


VERIFICATION OF TRANSLATION

I, Shoji MIWA, a patent attorney of c/o Subaru Patent Office, Kojimachi Koyo Bldg., 10, Kojimachi 1-chome, Chiyoda-ku, Tokyo, Japan, hereby declare:

1. that I know well both the Japanese and English languages;
2. that the attached English translation is a true and correct translation of Japanese Patent Application No. 2000-321822 filed on October 20, 2000, priority of which is claimed in US Patent Application Serial No. 10/645,085 (Filing or 371 (c) Date: October 7, 2002), to the best of my knowledge and belief; and
3. that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 USC 1001, and that such false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: July 24, 2006

By:   
Shoji MIWA

CERTIFIED COPY OF  
PRIORITY DOCUMENT

PATENT OFFICE  
JAPANESE GOVERNMENT

This is to certify that the annexed is a true copy of the following application as filed with this Office.

Date of Application: October 20, 2000

Japanese Patent Application Number: 2000-321822

Applicant(s): CHUGAI SEIYAKU KABUSHIKI KAISHA

Commissioner,

Patent Office

(Seal)

[Document] Patent Application  
[Case No.] DOJ-5467  
[Filing Date] October 20, 2000  
[To] Commissioner of the Patent Office Esq.  
[IPC] C07K 15/28  
C12N 5/16  
C12N 5/20  
C12N 15/06  
C12N 15/07  
C12N 15/09  
C12N 15/13  
C12N 21/08  
A61K 38/175

[Inventor]

[Address] c/o Chugai Seiyaku Kabushiki Kaisha,  
135, Komakado 1-chome, Gotemba-shi, Shizuoka-ken, Japan

[Name] **Naoshi FUKUSHIMA**

[Inventor]

[Address] c/o Chugai Seiyaku Kabushiki Kaisha,  
135, Komakado 1-chome, Gotemba-shi, Shizuoka-ken, Japan

[Name] **Masayuki TSUCHIYA**

[Inventor]

[Address] c/o Chugai Seiyaku Kabushiki Kaisha,  
135, Komakado 1-chome, Gotemba-shi, Shizuoka-ken, Japan

[Name] **Masayoshi OHEDA**

[Inventor]

[Address] c/o Chugai Seiyaku Kabushiki Kaisha,

135, Komakado 1-chome, Gotemba-shi, Shizuoka-ken, Japan

[Name] **Shinsuke UNO**

[Inventor]

[Address] c/o Chugai Seiyaku Kabushiki Kaisha,  
135, Komakado 1-chome, Gotemba-shi, Shizuoka-ken, Japan

[Name] **Yasufumi KIKUCHI**

[Applicant]

[ID No.] 000003311

[Name] **CHUGAI SEIYAKU KABUSHIKI KAISHA**

[Agent]

[Registration No.] 100091731

[Patent Attorney]

[Name] Chiyoshi TAKAGI

[Phone No.] 03-3261-2022

[Appointed Agent]

[Registration No.] 100080355

[Patent Attorney]

[Name] Tadasuke NISHIMURA

[Appointed Agent]

[Registration No.] 100110593

[Patent Attorney]

[Name] Hiroshi SUGIMOTO

[Priority Claim]

[Application No.] JP 2000-115246

[Filing Date] April 17, 2000

[Designation of Official Fee]

[Ledger No.] 015565

[Amount of Payment] 21,000 yen

[Inventory of Submitted Documents]

[Article] Specification 1

[Article] Drawing(s) 1

[Article] Abstract 1

[General Power of Attorney Number] 0002667

[Proof] Yes

[Document] SPECIFICATION

[TITLE OF THE INVENTION] POLYPEPTIDE INDUCING APOPTOSIS

[Claims]

[Claim 1] A reconstructed polypeptide which binds to  
5 Integrin Associated Protein (IAP), induces apoptosis of  
nucleated blood cells and causes no hemagglutination.

[Claim 2] The reconstructed polypeptide of claim 1, wherein  
the reconstructed polypeptide is a reshaped antibody.

10 [Claim 3] The reconstructed polypeptide of claim 2, wherein  
the reshaped antibody comprises two or more H chain V  
regions and two or more L chain V regions of the monoclonal  
antibody.

15 [Claim 4] The reconstructed polypeptide of claim 3, wherein  
the reconstituted polypeptide is a dimer of a single-chain  
Fv comprising an H chain V region and an L chain V region.

[Claim 5] The reconstructed polypeptide of any one of claims  
1 to 4, wherein the reconstituted polypeptide is a purified  
dimer of a single-chain Fv.

20 [Claim 6] The reconstructed polypeptide of claim 3, wherein  
the polypeptide is a single chain polypeptide comprising two  
H chain V regions and two L chain V regions.

[Claim 7] The reconstructed polypeptide of claim 5 or 6,  
wherein the H chain V region and the L chain V region are  
linked with a linker comprising at least one amino acid.

25 [Claim 8] A DNA encoding the single-chain Fv of any one of  
claims 4, 5 and 7.

[Claim 9] A DNA encoding the polypeptide of claim 6 or 7

[Claim 10] The reconstructed polypeptide of any one of claims 1 to 3, wherein the H chain V region and/or the L chain V region are humanized.

[Claim 11] A DNA encoding the polypeptide of claim 10.

5 [Claim 12] An animal cell which produces the reconstructed polypeptide of any one of claims 1, 2, 3, 4, 5, 6, 7 and 10.

[Claim 13] A microorganism which produces the reconstructed polypeptide of any one of claims 1, 2, 3, 4, 5, 6, 7 and 10.

10 [Claim 14] A therapeutic agent for blood dyscrasia which comprises the reconstructed polypeptide of one of claims 1, 2, 3, 4, 5, 6, 7 and 10 as an active ingredient.

[Claim 15] The therapeutic agent of claim 14 characterized in that the blood dyscrasia is leukemia.

15 [Claim 16] The therapeutic agent of claim 14 characterized in that the active ingredient is the single-chain Fv of any one of claims 4, 5 and 7.

[DETAILED EXPLANATION OF THE INVENTION]

[0001]

[TECHNICAL FIELD TO WHICH THE INVENTION BELONGS]

This invention relates to a reconstructed polypeptide with a property of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. More specifically, the present invention relates to the reconstructed polypeptide comprising two or more H chain V regions and two or more L chain V regions of a monoclonal antibody inducing apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.

[0002]

[BACKGROUND ART]

The inventors of this invention tried to prepare a specific monoclonal antibody using a splenic stromal cell line as a sensitizing antigen aiming at developing specific antibodies that can recognize the aforementioned splenic stromal cells and succeeded in the preparation of novel monoclonal antibodies that recognize mouse Integrin Associated Protein (mouse IAP) as an antigen. Then the study of the activity of said antibodies using recombinant cells into which the gene of mouse IAP was introduced led to the finding that the monoclonal antibodies are capable of inducing apoptosis of myeloid cells. (Japanese Patent Application 9-67499)

[0003]

Further the inventors prepared hybridomas MABL-1 (FERM BP-6100) and MABL-2 (FERM BP-6101) producing the monoclonal antibodies whose antigen is human Integrin Associated Protein (hereinafter referred to as human IAP; amino acid sequence and nucleotide sequence thereof are described in J. Cell Biol., 123, 485-496, 1993; see also Journal of Cell Science, 108, 3419-3425, 1995) and which are capable of inducing apoptosis of human nucleated blood cells (myeloid cell and lymphocyte) having said human IAP and named the monoclonal antibodies MABL-1 and MABL-2, respectively. These monoclonal antibodies are referred to antibody. (WO99/12973)

[0004]

The inventors diligently searched to produce therapeutic agent of the above-mentioned blood-related diseases from the monoclonal antibodies whose antigen is human IAP and obtained single-chain Fvs having single chain Fv regions which are capable of inducing apoptosis of nucleated blood cells having human IAP. (Japanese Patent Application 11-63557)

[0005]

Further it was found that the monoclonal antibodies recognizing IAP as an antigen induce apoptosis of nucleated blood cells having human IAP when administered, but they also cause hemagglutination in vitro. It indicates that the administration of a large amount of the monoclonal

antibody recognizing IAP as an antigen may result in a side effect such as hemagglutination.

[0006]

[PROBLEM TO BE SOLVED BY THE INVENTION]

5                   Therefore this invention is to provide reconstructed polypeptides with improved property of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and with decreased or completely eliminated property of causing hemagglutination. Further the 10 present invention is to provide therapeutic agents for blood dyscrasia comprising the substance obtained above which induces apoptosis of nucleated blood cells having Integrin Associated Protein (IAP).

[0007]

15                  [MEANS TO SOLVE THE PROBLEM]

Therefore, the present invention relates to the reconstructed polypeptides which binds to Integrin Associated Protein (IAP), induces apoptosis of nucleated blood cells having IAP and causes no hemagglutination.

20                  [0008]

The invention relates also to the reconstructed polypeptides, reshaped antibodies.

[0009]

25                  The reshaped antibody may include any reconstructed polypeptide which comprises an L chain V region and an H chain V region derived from a monoclonal antibody, e.g. antibody MABL-1, antibody MABL-2 or the like

inducing apoptosis of nucleated blood cells having IAP,  
preferably human IAP, which polypeptide induces apoptosis of  
nucleated blood cells having IAP, preferably human IAP and  
causes no hemagglutination. Further, the present invention  
5 also includes reconstructed polypeptides wherein an amino  
acid sequence of the V region is partially altered.

[0010]

The present invention also relates to the  
humanization of the reconstructed polypeptide. The humanized  
10 reconstructed polypeptide comprises a humanized L chain V  
region and/or a humanized H chain V region. Specifically,  
the humanized polypeptide of the invention consists of the  
humanized L chain V region which comprises a framework  
region (FR) derived from an L chain V region of human  
15 monoclonal antibody and an CDR derived from an L chain V  
region of mouse monoclonal antibody and/or the humanized H  
chain V region which comprises an FR derived from an H chain  
V region of human monoclonal antibody and a CDR derived from  
an H chain V region of mouse monoclonal antibody. In this  
20 case, the amino acid sequence of FR or CDR may be partially  
altered, e.g. deleted, replaced or added.

[0011]

Furthermore, the present invention relates to  
reconstructed polypeptides capable of inducing apoptosis of  
25 nucleated blood cells having human IAP, which polypeptides  
comprise an L chain C region of human antibodies and an L  
chain V region of the mouse monoclonal antibodies, and/or an

H chain C region of human antibodies and an H chain V region of the mouse monoclonal antibodies.

[0012]

The present invention also relates to  
5 reconstructed polypeptides inducing apoptosis of nucleated blood cells having human IAP, which polypeptides comprise a CDR derived from a monoclonal antibody of other mammals than mouse such as human, rat, bovine, sheep or the like, which corresponds to the aforementioned mouse CDR, or an L chain V 10 region and an H chain V region which contain the aforementioned CDR. Such CDRs, L chain V regions and H chain V regions may include CDRs derived from a human monoclonal antibody prepared from, for example, a transgenic mouse or the like, and L chain V regions and H chain V regions 15 derived from a human monoclonal antibody containing the aforementioned CDR.

[0013]

The invention also relates to DNAs encoding the various reconstructed polypeptides as aforementioned and 20 genetic engineering techniques for the production of recombinant vectors comprising the DNAs.

[0014]

The invention also relates to host cells transformed with the recombinant vectors. Examples of host 25 cells mammalian cells such as human cells, mouse cells or the like and microorganisms such as E. coli, Bacillus subtilis, yeast or the like.

[0015]

The invention relates to a process for producing the reconstructed polypeptides, which comprises culturing the above hosts and extracting the reconstructed polypeptides from the culture thereof.

5

[0016]

The present invention relates to therapeutic agents for blood dyscrasia comprising as an active ingredient the reconstructed polypeptide obtained in the above which induces apoptosis of nucleated blood cells having Integrin Associated Protein (IAP). The therapeutic agents for blood dyscrasia of the invention are useful for the treatment of blood dyscrasia, for example, leukemia such as acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia and hairy cell leukemia, malignant lymphoma (Hodgkin's disease, non-Hodgkin's lymphoma), aplastic anemia, myelodysplasia syndrome and polycythemia vera.

15

[0017]

[EMBODIMENT OF THE INVENTION]

The reconstructed polypeptides of the present invention preferably comprise two H chain V regions and two L chain V regions derived from the monoclonal antibodies. The structure of the reconstructed polypeptides may be a dimer of single-chain Fv comprising one H chain V region and one L chain V region or a polypeptide comprising two H chain

20

25

V regions and two L chain V regions. In the reconstructed polypeptides of the invention, the H chain V region and the L chain V region are preferably linked through a peptide linker which consists of one or more amino acids. The resulting reconstructed polypeptides contain variable regions of the parent antibodies and retain the complementarity determining region (CDR) thereof, and therefore bind to the antigen with the same specificity as that of the parent monoclonal antibodies.

10 [0018]

H chain V region

In the present invention, the H chain V region derived from the monoclonal antibody can be the H chain V region of the monoclonal antibody inducing apoptosis of nucleated blood cells having IAP or the H chain V region whose amino acid sequence is partially modified, preferably the H chain V region of the monoclonal antibody recognizing human IAP and inducing apoptosis of nucleated blood cells having IAP or the H chain V region whose amino acid sequence is partially modified. Preferable is the H chain V region derived from antibody MABL-1 or antibody MABL-2, or the H chain V region wherein the amino acid sequence of the H chain V region is partially modified. More preferable is humanized H chain V region comprising FR from an H chain V region of human monoclonal antibody and CDR from the H chain V region of mouse monoclonal antibody. The H chain V region further can be an H chain V region derived from a human

monoclonal antibody corresponding to the aforementioned H chain V region of mouse monoclonal antibody, which can be produced by recombination technique. The H chain V region of the invention may be a fragment of aforementioned H chain V region, which fragment preserves the antigen binding capacity.

5 [0019]

L chain V region

The L chain V region of the present invention can be L chain V region of the monoclonal antibody inducing apoptosis of nucleated blood cells having IAP or the L chain V region wherein the amino acid sequences of the L chain V region is partially modified, preferably the L chain V region of the monoclonal antibody recognizing human IAP and inducing apoptosis of nucleated blood cells having IAP or the L chain V region whose amino acid sequences is partially modified. Preferable is L chain V region derived from antibody MABL-1 or antibody MABL-2, or its L chain V region whose amino acid sequence is partially modified. More preferable is humanized L chain V region comprising FR from L chain V region of human monoclonal antibody and CDR from the L chain V region of mouse monoclonal antibody. The L chain V regions further can be an L chain V region derived from human monoclonal antibody corresponding to the aforementioned L chain V region of mouse monoclonal antibody, which can be produced by recombination technique. The L chain V regions of the invention may be fragments of L

chain V region, which fragments preserve the antigen binding capacity.

[0020]

Complementarity determining region (CDR)

5           Each V region of L chain and H chain forms an antigen-binding site. The variable region of the L and H chains is composed of comparatively conserved four common framework regions linked to three hypervariable regions or complementarity determining regions (CDR) (Kabat, E.A. et al., "Sequences of Protein of Immunological Interest", US  
10          Dept. Health and Human Services, 1983).

[0021]

Major portions in the four framework regions (FRs) form  $\beta$ -sheet structures and thus three CDRs form a loop.  
15          CDRs may form a part of the  $\beta$ -sheet structure in certain cases. The three CDRs are held sterically close position to each other by FR, which contributes to the formation of the antigen-binding site together with three CDRs.

[0022]

20          These CDRs can be identified by comparing the amino acid sequence of V region of the obtained antibody with known amino acid sequences of V regions of known antibodies according to the empirical rule in Kabat, E.A. et al., "Sequences of Protein of Immunological Interest".

25          [0023]

Single-chain Fv

A single-chain Fv is a polypeptide monomer comprising an H chain V region and an L chain V region linked each other which are derived from monoclonal antibodies. The resulting single-chain Fvs contain variable regions of the parent monoclonal antibodies and preserve the complementarity determining region thereof, and therefore the single-chain Fvs bind to the antigen by the same specificity as that of the parent monoclonal antibodies (JP-Appl. 11-63557). A part of the variable region and/or CDR of the single-chain Fv of the invention or a part of the amino acid sequence thereof may be partially altered, for example deleted, replaced or added. The H chain V region and L chain V region composing the single-chain Fv of the invention are mentioned before and may be linked directly or through a linker, preferably a peptide linker. The constitution of the single-chain Fv may be [H chain V region]-[L chain V region] or [L chain V region]-[H chain V region]. In the present invention, the single-chain Fv can form a dimer, trimer or which can be tetramer included in the reconstructed polypeptide of the invention.

[0024]

Single-chain reconstructed polypeptide

The single-chain reconstructed polypeptides of the present invention comprising two or more H chain V regions and two or more L chain V regions comprise two or more H chain V regions and L chain V regions as mentioned above. Each region of the peptide should be arranged such that the

reconstructed single chain polypeptide forms a specific  
steric structure, concretely mimicking a steric structure  
formed by the dimer of single-chain Fv. For instance, the V  
regions are arranged in the order of the following manner:

5 [H chain V region]-[L chain V region]-[H chain V region]-[L  
chain V region]; or

[L chain V region]-[H chain V region]-[L chain V region]-[H  
chain V region],

10 wherein these regions are connected through a peptide  
linker, respectively.

[0025]

Linker

In this invention, the linkers for the connection  
between the H chain V region and the L chain V region may be  
15 any peptide linker which can be introduced by the genetic  
engineering procedure or any linker chemically synthesized.  
For instance, linkers disclosed in literatures, e.g. Protein  
Engineering, 9(3), 299-305, 1996 may be used in the  
invention. Examples of the peptide linkers may include, for  
20 example;

Ser

Gly-Ser

Gly-Gly-Ser

Ser-Gly-Gly

25 Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly-Gly  
Gly-Gly-Gly-Gly-Gly-Ser  
Ser-Gly-Gly-Gly-Gly-Gly  
Gly-Gly-Gly-Gly-Gly-Gly-Ser  
5 Ser-Gly-Gly-Gly-Gly-Gly-Gly  
(Gly-Gly-Gly-Gly-Ser)<sub>n</sub> and  
(Ser-Gly-Gly-Gly-Gly)<sub>n</sub>

wherein n is an integer not less than one. Length of the peptide linker is in the range of 1 to 15 amino acids, preferably 2 to 12 amino acids, more preferably 3 to 10 amino acids. Procedures for introducing these linkers are mentioned in Explanation of DNA encoding the reconstructed polypeptide or the invention.

[0026]

15 The chemically synthesized linkers, i.e. the chemical crosslinking agents, according to the invention can be any linkers conventionally employed for the linkage of peptides. Examples of the linkers may include N-hydroxy succineimide (NHS), disuccinimidyl suberate (DSS),  
20 bis(sulfosuccinimidyl)suberate (BS<sup>3</sup>), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycolbis(succinimidyl succinate) (EGS), ethylene glycolbis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimido oxycarbonyloxy)ethyl]sulfone (BSOCOES), bis[2-(sulfosuccinimido oxycarbonyloxy)

ethyl]sulfone (sulfo-BSOCOES) or the like. These are commercially available.

[0027]

To form a dimer of the single-chain Fv it is preferable to use a linker to efficiently produce a dimer, specifically a linker composed of 2 to 12 amino acids, preferably 3 to 10 amino acids or other linkers corresponding thereto.

[0028]

Preparation of reconstructed polypeptides

The reconstructed polypeptide binding to cells with human IAP are obtainable by connecting an H chain V region and an L chain V region derived from monoclonal antibodies against human IAP through the aforementioned linker. Examples of the single-chain Fvs are MABL1-scFv comprising the H chain V region and the L chain V region derived from the antibody MABL-1, and MABL2-scFv comprising the H chain V region and the L chain V region derived from the antibody MABL-2.

[0029]

For the preparation of the reconstructed polypeptide, a signal peptide may be attached to N-terminal of the polypeptide where the polypeptide is desired to be a secretory peptide. A well-known amino acid sequence useful for the purification of polypeptide such as the FLAG sequence may be attached for the efficient purification of

the polypeptide. The polypeptide can be efficiently purified with anti-FLAG antibody.

[0030]

For the preparation of the reconstructed polypeptide of the invention, it is necessary to obtain a DNA encoding the reconstructed polypeptide, i.e. a DNA encoding the single-chain Fv or a DNA encoding the reconstructed polypeptide monomer. These DNAs are obtainable from the DNAs encoding the H chain V region and the L chain V region of MABL1-scFv and/or MABL2-scFv. They are also obtainable by amplifying a DNA encoding desired amino acid sequence within the aforementioned sequence by PCR using the DNA as a template and a pair of primers corresponding to both ends thereof.

[0031]

In the case where each V region having partially modified amino acid sequence is desired, the V regions in which one or some amino acids are modified, i.e. deleted, replaced or added can be obtained by a procedure known in the art using PCR. A part of the amino acid sequence in the V region is preferably modified by the PCR known in the art in order to prepare the reconstructed polypeptide which is sufficiently active against the specific antigen.

[0032]

For the determination of primers for the PCR amplification, it is necessary to decide the type of the H chain and L chain of the antibody MABL-1 and/or the antibody

MABL-2. It has been reported, however, that the antibody MABL-1 has  $\kappa$  type L chains and  $\gamma_1$  type H chains and the antibody MABL-2 has  $\kappa$  type L chains and  $\gamma_2\alpha$  type H chains (JP-Appl. 11-63557). For the PCR amplification of the DNA encoding the H chain and L chain of the antibody MABL-1 and/or the antibody MABL-2, primers described in Jones, S.T. et al., Bio/Technology, 9, 88-89, 1991 may be employed.

5 [0033]

For the amplification of the L chain V regions of the antibody MABL-1 and the antibody MABL-2 using the polymerase chain reaction (PCR), 5'-end and 3'-end oligonucleotide primers are decided as aforementioned. In the same manner, 5'-end and 3'-end oligonucleotide primers are decided for the amplification of the H chain V regions 15 of the antibody MABL-1 and the antibody MABL-2.

[0034]

In embodiments of the invention, the 5'-end primers which contain a sequence "GANTC" providing the restriction enzyme Hinf I digestion site at the neighborhood 20 of 5'-terminal thereof are used and the 3'-end primers which contain a nucleotide sequence "CCCGGG" providing the XmaI digestion site at the neighborhood of 5'-terminal thereof are used. Other restriction enzyme digestion sites may be used instead of these sites as long as they are used for 25 subcloning a desired DNA fragment into a cloning vector.

[0035]

Specifically designed PCR primers are employed to provide suitable nucleotide sequences at 5'-end and 3'-end of the cDNAs encoding the V regions of the antibodies MABL-1 and MABL-2 so that the cDNAs are readily inserted into an expression vector and appropriately function in the expression vector (e.g. this invention devises to increase transcription efficiency by inserting Kozak sequence). The V regions of the antibodies MABL-1 and MABL-2 obtained by amplifying by PCR using these primers are inserted into HEF expression vector containing the desired human C region (see WO92/19759). The cloned DNAs can be sequenced by using any conventional process which comprises, for example, inserting the DNAs into a suitable vector and then sequencing using the automatic DNA sequencer (Applied Biosystems).

[0036]

A linker such as a peptide linker can be introduced into the reconstructed polypeptide of the invention in the following manner. Primers which have partially complementary sequence with the primers for the H chain V regions and the L chain V regions as described above and which code for the N-terminal or the C-terminal of the linker are designed. Then, the PCR procedure can be carried out using these primers to prepare a DNA encoding the peptide linker having desired amino acid sequence and length. The DNAs encoding the H chain V region and the L chain V region can be connected through the resulting DNA to produce the DNA encoding the reconstructed polypeptide of

the invention which has the desired peptide linker. Once the DNA encoding one of the reconstructed polypeptides is prepared, the DNAs encoding the reconstructed polypeptides with or without the desired peptide linker can readily be produced by designing various primers for the linker and then carrying out the PCR using the primers and the aforementioned DNA as a template.

[0037]

Each V region of the reconstructed polypeptide of the present invention can be humanized by using conventional techniques (e.g. Sato, K. et al., Cancer Res., 53, 851-856 (1993)). Once a DNA encoding a humanized Fv is prepared, a humanized single-chain Fv, a fragment of the humanized single-chain Fv, a humanized monoclonal antibody and a fragment of the humanized monoclonal antibody can readily be produced according to conventional methods. Preferably, amino acid sequences of the V regions thereof may be partially modified, if necessary.

[0038]

Furthermore, a DNA derived from other mammalian origin, for example a DNA of human, can be produced in the same manner as used to produce DNA encoding the H chain V region and the L chain V region derived from mouse mentioned in the above. The resulting DNA can be used to prepare an H chain V region and an L chain V region of other mammal, especially human origin, a single-chain Fv derived from

human and a fragment thereof, and a monoclonal antibody of human origin and a fragment thereof.

[0039]

As mentioned above, when the aimed DNAs encoding the V regions of the reconstructed polypeptides and the V regions the reconstructed humanized polypeptides are prepared, the expression vectors containing them and hosts transformed with the vectors can be obtained according to conventional methods. Further, the hosts can be cultured according to a conventional method to produce the reconstructed single-chain Fv, the reconstructed humanized single-chain Fv, the humanized monoclonal antibodies and fragments thereof. They can be isolated from cells or a medium and can be purified into a homogeneous mass. For this purpose any isolation and purification methods conventionally used for proteins, e.g. chromatography, ultra-filtration, salting-out and dialysis, may be employed in combination, if necessary, without limitation thereto.

[0040]

For the production of the reconstructed polypeptides binding to cells with human IAP of the present invention, any expression systems can be employed, for example, eukaryotic cells such as animal cells, e.g., established mammalian cell lines, filamentous fungi and yeast, and prokaryotic cells such as bacterial cells e.g., E. coli. Preferably, the reconstructed polypeptides of the

invention are expressed in mammalian cells, for example COS7 cells or CHO cells.

[0041]

In these cases, conventional promoters useful for the expression in mammalian cells can be used. Preferably, 5 human cytomegalovirus (HCMV) immediate early promoter is used. Expression vectors containing the HCMV promoter include HCMV-VH-HC $\gamma$  1, HCMV-VL-HCK and the like which are derived from pSV2neo (WO92/19759).

10 [0042]

Additionally, other promoters for gene expression in mammal cell which may be used in the invention include virus promoters derived form retrovirus, polyoma virus, adenovirus and simian virus 40 (SV40) and promoters derived 15 from mammal such as human polypeptide-chain elongation factor-1 $\alpha$  (HEF-1 $\alpha$ ). SV40 promoter can easily be used according to the method of Mulligan, R.C., et al. (Nature 277, 108-114 (1979)) and HEF-1 $\alpha$  promoter can also be used according to the methods of Mizushima, S. et al. (Nucleic 20 Acids Research, 18, 5322 (1990)).

[0043]

Replication origin (ori) which can be used in the invention includes ori derived from SV40, polyoma virus, adenovirus, bovine papilloma virus (BPV) and the like. For 25 the purpose of the amplification of gene copy number in the host cell system and the like, an expression vector may contain, as a selection marker, phosphotransferase APH (3')

II or I (neo) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyl transferase (Ecogpt) gene or dihydrofolate reductase (DHFR) gene.

[0044]

5                 The antigen-binding activity of the reconstructed polypeptide as prepared above can be evaluated using the binding-inhibitory ability of the mouse antibodies, MABL-1 and MABL-2, to human IAP as an index. Concretely, the activity is evaluated in terms of the absence or presence of  
10 concentration-dependent inhibition of the binding of the mouse antibody MABL-2 to human IAP antigen as an index.

[0045]

15                 More in detail, animal cells transformed with an expression vector containing a DNA encoding the reconstructed polypeptide of the invention, e.g., COS7 cells or CHO cells, are cultured. The cultured cells and/or the supernatant of the medium or the reconstructed polypeptide purified from them are used to determine the binding to antigen. As a control, a supernatant of the cultural medium  
20 is used in which cells transformed only with the expression vector were cultured. A test sample of the reconstructed polypeptide of the invention or the supernatant of the control is added to mouse leukemia cell line, L1210 cells, expressing human Integrin Associated Protein (IAP) and then  
25 an assay such as the flow cytometry is carried out to evaluate the antigen-binding activity.

[0046]

The apoptosis-inducing effect in vitro is evaluated in the following manner: A test sample of the above reconstructed polypeptide is added to the cells into which the human IAP gene has been introduced and is evaluated on its inducibility of human IAP-specific cell death in the cells.

[0047]

The apoptosis-inducing effect in vivo is evaluated in the following manner: A mouse model of human myeloma is prepared. To the mice is intravenously administered the monoclonal antibody or the reconstructed polypeptide of the invention, which induces apoptosis of nucleated blood cells having IAP. To mice of a control group is administered PBS alone. The induction of apoptosis is evaluated in terms of antitumor effect based on the change of human IgG content in serum of the mice and their survival time.

[0048]

Hemagglutination effect is tested in the following manner: A suspension of erythrocytes is prepared from blood of healthy donors. Test samples of different concentrations are added to the suspension, which are then incubated to determine the hemagglutination.

[0049]

Reconstructed polypeptides of the invention, which comprises two or more H chain V regions and two or more L chain V regions, may be a dimer, trimer or tetramer of the single-chain Fv comprising one H chain V region and one L

chain V region, or a polypeptide in which two or more H chain V regions and two or more L chain V regions are connected. It is considered that owing to such construction the peptide mimics three dimensional structure of the antigen binding site of the parent monoclonal antibody and therefore retains an excellent antigen-binding property.

5 [0050]

The polypeptide of the invention has a superior mobility to tissues or tumors over whole IgG and a remarkably reduced or no side effect of hemagglutination. Therefore, it is expected that the peptide of the invention can be used as a therapeutic agent for blood dyscrasia, for example, leukemia such as acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia and hairy cell leukemia, malignant lymphoma (Hodgkin's disease, non-Hodgkin's lymphoma), hypoplastic anemia, osteomyelodysplasia and polycythemia vera. It is further expected that the peptide of the invention can be used as a contrast agent by RI-labeling. The effect of the peptide can be enhanced by attaching to a RI-compound or a toxin.

20 [0051]

The present invention will concretely be illustrated in reference to the following examples, which in no way limit the scope of the invention.

25 [0052]

[EXAMPLES]

For illustrating the production process of the reconstructed polypeptides of the invention, examples of producing single-chain Fvs are shown below. Mouse antibodies against human IAP, MABL-1 and MABL-2 were used in the examples of producing the reconstructed polypeptides.

Hybridomas MABL-1 and MABL-2 producing them respectively were internationally deposited as FERM BP-6100 and FERM BP-6101 with the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Minister of International Trade and Industry (1-3 Higasi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan), an authorized depository for microorganisms, on September 11, 1997.

[0053]

Example 1 (Cloning of DNAs encoding V region of mouse monoclonal antibodies to human IAP)

DNAs encoding variable regions of the mouse monoclonal antibodies to human IAP, MABL-1 and MABL-2, were cloned as follows.

[0054]

1.1 Preparation of messenger RNA (mRNA)

mRNAs of the hybridomas MABL-1 and MABL-2 were obtained by using mRNA Purification Kit (Pharmacia Biotech).

[0055]

1.2 Synthesis of double-stranded cDNA

Double-stranded cDNA was synthesized from about 1 µg of the mRNA using Marathon cDNA Amplification Kit (CLONTECH) and an adapter was linked thereto.

[0056]

5       1.3 PCR Amplification of genes encoding variable regions of an antibody by

PCR was carried out using Thermal Cycler (PERKIN ELMER).

[0057]

10      (1) Amplification of a gene coding for L chain V region of MABL-1

15      Primers used for the PCR method are Adapter Primer-1 (CLONTECH) shown in SEQ ID No. 1, which hybridizes to a partial sequence of the adapter, and MKC (Mouse Kappa Constant) primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No. 2, which hybridizes to the mouse kappa type L chain V region.

[0058]

20      50 µl of the PCR solution contains 5 µl of 10 × PCR Buffer II, 2 mM MgCl<sub>2</sub>, 0.16 mM dNTPs (dATP, dGTP, dCTP and dTTP), 2.5 units of a DNA polymerase, AmpliTaq Gold (PERKIN ELMER), 0.2 µM of the adapter primer of SEQ ID No. 1, 0.2 µM of the MKC primer of SEQ ID No. 2 and 0.1 µg of the double-stranded cDNA derived from MABL-1. The solution 25 was preheated at 94°C of the initial temperature for 9 minutes and then heated at 94°C for 1 minute, at 60°C for 1 minute and at 72°C for 1 minute 20 seconds in order. This

temperature cycle was repeated 35 times and then the reaction mixture was further heated at 72°C for 10 minutes.

[0059]

(2) Amplification of cDNA encoding H chain V region of MABL-

5       1

The Adapter Primer-1 shown in SEQ ID No. 1 and MHC- $\gamma$ 1 (Mouse Heavy Constant) primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No. 3 were used as primers for PCR.

10      [0060]

The amplification of cDNA was performed according to the method of the amplification of the L chain V region gene, which was described in Example 1.3-(1), except for using 0.2  $\mu$ M of the MHC- $\gamma$ 1 primer instead of 0.2  $\mu$ M of the MKC primer.

15      [0061]

(3) Amplification of cDNA encoding L chain V region of MABL-

20       2

The Adapter Primer-1 of SEQ ID No. 1 and the MKC primer of SEQ ID No. 2 were used as primers for PCR.

25      [0062]

The amplification of cDNA was carried out according to the method of the amplification of the L chain V region gene of MABL-1 which was described in Example 1.3-(1), except for using 0.1  $\mu$ g of the double-stranded cDNA derived from MABL-2 instead of 0.1  $\mu$ g of the double-stranded cDNA from MABL-1.

[0063]

(4) Amplification of cDNA encoding H chain V region of MABL-

2

The Adapter Primer-1 of SEQ ID No. 1 and MHC- $\gamma$ 2a  
5 primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No.  
4 were used as primers for PCR.

[0064]

The amplification of cDNA was performed according  
to the method of the amplification of the L chain V region  
10 gene, which was described in Example 1.3-(3), except for  
using 0.2  $\mu$ M of the MHC- $\gamma$ 2a primer instead of 0.2  $\mu$ M of the  
MKC primer.

[0065]

1.4 Purification of PCR products

15 The DNA fragment amplified by PCR as described  
above was purified using the QIAquick PCR Purification Kit  
(QIAGEN) and dissolved in 10 mM Tris-HCl (pH 8.0) containing  
1 mM EDTA.

[0066]

20 1.5 Ligation and Transformation

About 140 ng of the DNA fragment comprising the  
gene encoding the mouse kappa type L chain V region derived  
from MABL-1 as prepared above was ligated with 50 ng of  
pGEM-T Easy vector (Promega) in the reaction buffer  
25 comprising 30 mM Tris-HCl (pH 7.8), 10 mM MgCl<sub>2</sub>, 10 mM  
dithiothreitol, 1 mM ATP and 3 units of T4 DNA Ligase  
(Promega) at 15°C for 3 hours.

[0067]

Then, 1  $\mu$ l of the reaction mixture was added to 50  $\mu$ l of E. coli DH5 $\alpha$  competent cells (Toyobo Inc.) and the cells were stored on ice for 30 minutes, incubated at 42°C for 1 minute and stored on ice for 2 minutes again. 100  $\mu$ l of SOC medium (GIBCO BRL) was added. The cells of E. coli were plated on LB (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989) agar medium containing 100  $\mu$ g/ml of ampicillin (SIGMA) and cultured at 37°C overnight to obtain the transformant of E. coli.

[0068]

The transformant was cultured in 3 ml of LB medium containing 50  $\mu$ g/ml of ampicillin at 37°C overnight and the plasmid DNA was prepared from the culture using the QIAprep Spin Miniprep Kit (QIAGEN).

[0069]

The resulting plasmid comprising the gene encoding the mouse kappa type L chain V region derived from the hybridoma MABL-1 was designated as pGEM-M1L.

[0070]

According to the same manner as described above, a plasmid comprising the gene encoding the mouse H chain V region derived from the hybridoma MABL-1 was prepared from the purified DNA fragment and designated as pGEM-M1H.

[0071]

A plasmid comprising the gene encoding the mouse kappa type L chain V region derived from the hybridoma MABL-2 was prepared from the purified DNA fragment and designated as pGEM-M2L.

5 [0072]

A plasmid comprising the gene encoding the mouse H chain V region derived from the hybridoma MABL-2 was prepared from the purified DNA fragment and designated as pGEM-M2H.

10 [0073]

Example 2 (DNA Sequencing)

The nucleotide sequence of the cDNA encoding region in the aforementioned plasmids was determined using Auto DNA Sequencer (Applied Biosystem) and ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystem) according to the manufacturer's protocol.

15 [0074]

The nucleotide sequence of the gene encoding the L chain V region from the mouse antibody MABL-1, which is included in the plasmid pGEM-M1L, is shown in SEQ ID No. 5.

20 [0075]

The nucleotide sequence of the gene encoding the H chain V region from the mouse antibody MABL-1, which is included in the plasmid pGEM-M1H, is shown in SEQ ID No. 6.

25 [0076]

The nucleotide sequence of the gene encoding the L chain V region from the mouse antibody MABL-2, which is included in the plasmid pGEM-M2L, is shown in SEQ ID No. 7.  
[0077]

5 The nucleotide sequence of the gene encoding the H chain V region from the mouse antibody MABL-2, which is included in the plasmid pGEM-M2H, is shown in SEQ ID No. 8.  
[0078]

Example 3 (Determination of CDR)

10 The V regions of L chain and H chain generally have a similarity in their structures and each four framework regions therein are linked by three hypervariable regions, i.e., complementarity determining regions (CDR). An amino acid sequence of the framework is relatively well conserved, while an amino acid sequence of CDR has extremely high variation (Kabat, E.A., et al., "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services, 1983).

15 [0079]

20 On the basis of these facts, the amino acid sequences of the variable regions from the mouse monoclonal antibodies to human IAP were applied to the database of amino acid sequences of the antibodies made by Kabat et al. to investigate the homology. The CDR regions were determined 25 based on the homology as shown in Table 1.

[0080]

Table 1

<u>Plasmid</u>	<u>SEQ ID No.</u>	<u>CDR (1)</u>	<u>CDR (2)</u>	<u>CDR (3)</u>
pGEM-M1L	5	43-58	74-80	113-121
pGEM-M1H	6	50-54	69-85	118-125
pGEM-M2L	7	43-58	74-80	113-121
5 pGEM-M2H	8	50-54	69-85	118-125

[0081]

Example 4 (Identification of Cloned cDNA Expression  
(Preparation of Chimera MABL-1 antibody and Chimera MABL-2  
antibody.)

10 4.1 Preparation of vectors expressing chimera MABL-1  
antibody

cDNA clones, pGEM-M1L and pGEM-M1H, encoding the V  
regions of the L chain and the H chain of the mouse antibody  
MABL-1, respectively, were modified by the PCR method and  
15 introduced into the HEF expression vector (WO92/19759) to  
prepare vectors expressing chimera MABL-1 antibody.

[0082]

A forward primer MLS (SEQ ID No. 9) for the L  
chain V region and a forward primer MHS (SEQ ID No. 10) for  
20 the H chain V region were designed to hybridize to a DNA  
encoding the beginning of the leader sequence of each V  
region and to contain the Kozak consensus sequence (J. Mol.  
Biol., 196, 947-950, 1987) and HindIII restriction enzyme  
site. A reverse primer MLAS (SEQ ID No. 11) for the L chain  
25 V region and a reverse primer MHAS (SEQ ID No. 12) for the H  
chain V region were designed to hybridize to a DNA encoding

the end of the J region and to contain the splice donor sequence and BamHI restriction enzyme site.

[0083]

100 µl of a PCR solution comprising 10 µl of 10 ×  
5 PCR Buffer II, 2 mM MgCl<sub>2</sub>, 0.16 mM dNTPs (dATP, dGTP, dCTP  
and dTTP), 5 units of DNA polymerase AmpliTaq Gold, 0.4 µM  
each of primers and 8 ng of the template DNA (pGEM-M1L or  
pGEM-M1H) was preheated at 94°C of the initial temperature  
for 9 minutes and then heated at 94°C for 1 minute, at 60°C  
10 for 1 minute and at 72°C for 1 minute 20 seconds in order.  
This temperature cycle was repeated 35 times and then the  
reaction mixture was further heated at 72°C for 10 minutes.

[0084]

The PCR product was purified using the QIAquick  
15 PCR Purification Kit (QIAGEN) and then digested with HindIII  
and BamHI. The product from the L chain V region was cloned  
into the HEF expression vector, HEF-κ and the product from  
the H chain V region was cloned into the HEF expression  
vector, HEF-γ. After DNA sequencing, plasmids containing a  
20 DNA fragment with a correct DNA sequence are designated as  
HEF-M1L and HEF-M1H, respectively.

[0085]

#### 4.2 Preparation of vectors expressing chimera MABL-2 antibodies

25 Modification and cloning of cDNA were performed in  
the same manner described in Example 4.1 except for using  
pGEM-M2L and pGEM-M2H as template DNA instead of pGEM-M1L

and pGEM-M1H. After DNA sequencing, plasmids containing DNA fragments with correct DNA sequences are designated as HEF-M2L and HEF-M2H, respectively.

[0086]

5       4.3 Transfection to COS7 cells

The aforementioned expression vectors were tested in COS7 cells to observe the transient expression of the chimera MABL-1 and MABL-2 antibodies.

[0087]

10      (1) Transfection with genes for the chimera MABL-1 antibody

COS7 cells were co-transformed with the HEF-M1L and HEF-M1H vectors by electroporation using the Gene Pulser apparatus (BioRad). Each DNA (10 µg) and 0.8 ml of PBS with  $1 \times 10^7$  cells/ml were added to a cuvette. The mixture was treated with pulse at 1.5 kV, 25 µF of electric capacity.

[0088]

15      After the restoration for 10 minutes at a room temperature, the electroporated cells were transferred into DMEM culture medium (GIBCO BRL) containing 10%  $\gamma$ -globulin-free fetal bovine serum. After culturing for 72 hours, the supernatant was collected, centrifuged to remove cell fragments and recovered.

[0089]

20      (2) Transfection with genes coding for the chimera MABL-2 antibody

The co-transfection to COS7 cells with the genes coding for the chimera MABL-2 antibody was carried out in

the same manner as described in Example 4.3-(1) except for using the HEF-M2L and HEF-M2H vectors instead of the HEF-M1L and HEF-M1H vectors. The supernatant was recovered in the same manner.

5 [0090]

#### 4.4 Flow cytometry

Flow cytometry was performed using the aforementioned culture supernatant of COS7 cells to measure binding to the antigen. The culture supernatant of the COS7 cells expressing the chimera MABL-1 antibody or the COS7 cells expressing the chimera MABL-2 antibody, or human IgG antibody (SIGMA) as a control was added to  $4 \times 10^5$  cells of mouse leukemia cell line L1210 expressing human IAP and incubated on ice. After washing, the FITC-labeled anti-human IgG antibody (Cappel) was added thereto. After incubating and washing, the fluorescence intensity thereof was measured using the FACScan apparatus (BECTON DICKINSON).

15 [0091]

Since the chimera MABL-1 and MABL-2 antibodies were specifically bound to L1210 cells expressing human IAP, it is confirmed that these chimera antibodies have proper structures of the V regions of the mouse monoclonal antibodies MABL-1 and MABL-2, respectively (Figures 1-3).

20 [0092]

Example 5 (Preparation of reconstructed Single-chain Fv (scFv) of the antibody MABL-1 and antibody MABL-2)

5.1 Preparation of reconstructed single-chain Fv of antibody

MABL-1

The reconstructed single-chain Fv of antibody MABL-1 was prepared as follows. The H chain V region and the L chain V of antibody MABL-1, and a linker were respectively amplified by the PCR method and were connected to produce the reconstructed single-chain Fv of antibody MABL-1. The production method is illustrated in Figure 4. Six primers (A-F) were employed for the production of the single-chain Fv of antibody MABL-1. Primers A, C and E have a sense sequence and primers B, D and F have an antisense sequence.

[0093]

The forward primer VHS for the H chain V region (Primer A, SEQ ID No. 13) was designed to hybridize to a DNA encoding the N-terminal of the H chain V region and to contain NcoI restriction enzyme recognition site. The reverse primer VHAS for H chain V region (Primer B, SEQ ID No. 14) was designed to hybridize to a DNA coding the C-terminal of the H chain V region and to overlap with the linker.

[0094]

The forward primer LS for the linker (Primer C, SEQ ID No. 15) was designed to hybridize to a DNA encoding the N-terminal of the linker and to overlap with a DNA encoding the C-terminal of the H chain V region. The reverse primer LAS for the linker (Primer D, SEQ ID No. 16) was designed to hybridize to a DNA encoding the C-terminal of

the linker and to overlap with a DNA encoding the N-terminal of the L chain V region.

[0095]

The forward primer VLS for the L chain V region (Primer E, SEQ ID No. 17) was designed to hybridize to a DNA encoding the C-terminal of the linker and to overlap with a DNA encoding the N-terminal of the L chain V region. The reverse primer VLAS-FLAG for L chain V region (Primer F, SEQ ID No. 18) was designed to hybridize to a DNA encoding the C-terminal of the L chain V region and to have a sequence encoding the FLAG peptide (Hopp. T. P. et al., Bio/Technology, 6, 1204-1210, 1988), two stop codons and EcoRI restriction enzyme recognition site.

[0096]

In the first PCR step, three reactions, A-B, C-D and E-F, were carried out and PCR products thereof were purified. Three PCR products obtained from the first PCR step were assembled by their complementarity. Then, the primers A and F were added and the full length DNA encoding the reconstructed single-chain Fv of antibody MABL-1 was amplified. (Second PCR). In the first PCR, the plasmid pGEM-M1H encoding the H chain V region of antibody MABL-1 (see Example 2), a plasmid pSC-DP1 which comprises a DNA sequence encoding a linker region comprising: Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser (SEQ ID No. 19) (Huston, J.S., et al., Proc. Natl. Acad. Sci. USA, 85, 5879-5883, 1988) and the plasmid pGEM-M1L encoding the L chain V region

of antibody MABL-1 (see Example 2) were employed as template, respectively.

[0097]

5           50 µl of the solution for the first PCR step comprises 5 µl of 10 × PCR Buffer II, 2 mM MgCl<sub>2</sub>, 0.16 mM dNTPs, 2.5 units of DNA polymerase, AmpliTaq Gold (PERKIN ELMER), 0.4 µM each of primers and 5 ng each of template DNA. The PCR solution was preheated at 94°C of the initial temperature for 9 minutes and then heated at 94°C for 1  
10          minute, at 65°C for 1 minute and at 72°C for 1 minute and 20 seconds in order. This temperature cycle was repeated 35 times and then the reaction mixture was further heated at 72°C for 7 minutes.

[0098]

15          The PCR products A-B (371bp), C-D (63bp) and E-F (384bp) were purified using the QIAquick PCR Purification Kit (QIAGEN) and were assembled in the second PCR. In the second PCR, 98 µl of a PCR solution comprising 120 ng of the first PCR product A-B, 20 ng of the PCR product C-D and 120 ng of the PCR product E-F, 10 µl of 10 × PCR Buffer II, 2mM MgCl<sub>2</sub>, 0.16 mM dNTPs, 5 units of DNA polymerase AmpliTaq  
20          Gold (PERKIN ELMER) was preheated at 94°C of the initial temperature for 8 minutes and then heated at 94°C for 2 minutes, at 65°C for 2 minutes and at 72°C for 2 minutes in  
25          order. This temperature cycle was repeated twice and then 0.4 µM each of primers A and F were added into the reaction, respectively. The mixture was preheated at 94°C of the

initial temperature for 1 minutes and then heated at 94°C  
for 1 minute, at 65°C for 1 minute and at 72°C for 1 minute  
and 20 seconds in order. This temperature cycle was repeated  
35 times and then the reaction mixture was further heated at  
5 72°C for 7 minutes.

[0099]

A DNA fragment of 843 bp produced by the second  
PCR was purified and digested by NcoI and EcoRI. The  
resultant DNA fragment was cloned into pSCFVT7 vector. The  
10 expression vector pSCFVT7 contains a pelB signal sequence  
suitable for E. coli periplasmic expression system (Lei,  
S.P., et al., J. Bacteriology, 169, 4379-4383, 1987). After  
the DNA sequencing, the plasmid containing the DNA fragment  
encoding correct amino acid sequence of the reconstructed  
15 single-chain Fv of antibody MABL-1 is designated as "pscM1"  
(see Figure 5). The nucleotide sequence and the amino acid  
sequence of the reconstructed single-chain Fv of antibody  
MABL-1 contained in the plasmid pscM1 are shown in SEQ ID  
No. 20.

20 [0100]

The pscM1 vector was modified by the PCR method to  
prepare a vector expressing the reconstructed single-chain  
Fv of antibody MABL-1 in mammalian cells. The resultant DNA  
fragment was introduced into pCHO1 expression vector. This  
25 expression vector, pCHO1, was constructed by digesting DHFR-  
ΔE-rvH-PM1-f (WO92/19759) with EcoRI and SmaI to eliminate

the antibody gene and connecting the EcoRI-NotI-BamHI Adapter (Takara Shuzo) thereto.

[0101]

As a forward primer for PCR, Sal-VHS primer shown  
5 in SEQ ID No. 21 was designed to hybridize to a DNA encoding  
the N-terminal of the H chain V region and to contain SalI  
restriction enzyme recognition site. As a reverse primer for  
PCR, FRHlanti primer shown in SEQ ID No. 22 was designed to  
hybridize to a DNA encoding the end of the first framework  
10 sequence.

[0102]

100 µl of PCR solution comprising 10 µl of 10 ×  
PCR Buffer II, 2 mM MgCl<sub>2</sub>, 0.16 mM dNTPs, 5 units of the DNA  
polymerase, AmpliTaq Gold, 0.4 µl M each of primer and 8 ng  
15 of the template DNA (pscM1) was preheated at 95°C of the  
initial temperature for 9 minutes and then heated at 95°C  
for 1 minute, at 60°C for 1 minute and at 72°C for 1 minute  
and 20 seconds in order. This temperature cycle was repeated  
35 times and then the reaction mixture was further heated at  
20 72°C for 7 minutes.

[0103]

The PCR product was purified using the QIAquick  
PCR Purification Kit (QIAGEN) and digested by SalI and MboII  
to obtain a DNA fragment encoding the N-terminal of the  
25 reconstructed single-chain Fv of antibody MABL-1. The pscM1  
vector was digested by MboII and EcoRI to obtain a DNA  
fragment encoding the C-terminal of the reconstructed

single-chain Fv of antibody MABL-1. The SalI-MboII DNA fragment and the MboII-EcoRI DNA fragment were cloned into pCHO1-Igs vector. After DNA sequencing, the plasmid comprising the desired DNA sequence was designated as 5 "pCHOM1" (see Figure 6). The expression vector, pCHO1-Igs, contains a mouse IgG1 signal sequence suitable for the secretion-expression system in mammalian cells (Nature, 322, 323-327, 1988). The nucleotide sequence and the amino acid sequence of the reconstructed single-chain Fv of antibody 10 MABL-1 contained in the plasmid pCHOM1 are shown in SEQ ID No. 23.

[0104]

5.2 Preparation of reconstructed single-chain Fv of antibody MABL-2

15 The reconstructed single-chain Fv of antibody MABL-2 was prepared in accordance with the aforementioned Example 5.1. Employed in the first PCR step were plasmid pGEM-M2H encoding the H chain V region of MABL-2 (see Example 2) instead of pGEM-M1H and plasmid pGEM-M2L encoding 20 the L chain V region of MABL-2 (see Example 2) instead of pGEM-M1L, to obtain a plasmid pscM2 which comprises a DNA fragment encoding the desired amino acid sequence of the single-chain Fv of antibody MABL-2. The nucleotide sequence and the amino acid sequence of the reconstructed single- 25 chain Fv of antibody MABL-2 contained in the plasmid pscM2 are shown in SEQ ID No. 24.

[0105]

The pscM2 vector was modified by the PCR method to prepare a vector, pCHOM2, for the expression in mammalian cells which contains the DNA fragment encoding the correct amino acid sequence of reconstructed the single-chain Fv of antibody MABL-2. The nucleotide sequence and the amino acid sequence of the reconstructed single-chain Fv of antibody MABL-2 contained in the plasmid pCHOM2 are shown in SEQ ID No. 25.

[0106]

5.3 Transfection to COS7 cells

The pCHOM2 vector was tested in COS7 cells to observe the transient expression of the reconstructed single-chain Fv of antibody MABL-2.

[0107]

15 The COS7 cells were transformed with the pCHOM2 vector by electroporation using the Gene Pulser apparatus (BioRad). The DNA (10 µg) and 0.8 ml of PBS with  $1 \times 10^7$  cells/ml were added to a cuvette. The mixture was treated with pulse at 1.5 kV, 25 µF of electric capacity.

[0108]

20 After the restoration for 10 minutes at a room temperature, the electroporated cells were transferred into IMDM culture medium (GIBCO BRL) containing 10% fetal bovine serum. After culturing for 72 hours, the supernatant was collected, centrifuged to remove cell fragments and recovered.

[0109]

5.4 Detection of the reconstructed single-chain Fv of antibody MABL-2 in culture supernatant of COS7 cells

The existence of the single-chain Fv of antibody MABL-2 in the culture supernatant of COS7 cells which had been transfected with the pCHOM2 vector was confirmed by the Western Blotting method.

[0110]

The culture supernatant of COS7 cells transfected with the pCHOM2 vector and the culture supernatant of COS7 cells transfected with the pCHO1 as a control were subjected to SDS electrophoresis and transferred to REINFORCED NC membrane (Schleicher & Schuell). The membrane was blocked with 5% skim milk (Morinaga Nyu-gyo), washed with 0.05% Tween 20-PBS and mixed with an anti-FLAG antibody (SIGMA). The membrane was incubated at room temperature, washed and mixed with alkaline phosphatase-conjugated mouse IgG antibody (Zymed). After incubating and washing at room temperature, the substrate solution (Kirkegaard Perry Laboratories) was added to develop color (Figure 7).

[0111]

A FLAG-peptide-specific protein was detected only in the culture supernatant of the pCHOM2 vector-introduced COS7 cells and thus it is confirmed that the reconstructed single-chain Fv of antibody MABL-2 was secreted in this culture supernatant.

[0112]

5.5 Flow cytometry

Flow cytometry was performed using the aforementioned COS7 cells culture supernatant to measure the binding to the antigen. The culture supernatant of the COS7 cells expressing the reconstructed single-chain Fv of antibody MABL-2 or the culture supernatant of COS7 cells transformed with pCHO1 vector as a control was added to  $2 \times 10^5$  cells of the mouse leukemia cell line L1210 expressing human Integrin Associated Protein (IAP) or the cell line L1210 transformed with pCOS1 as a control. After incubating on ice and washing, the mouse anti-FLAG antibody (SIGMA) was added. Then the cells were incubated and washed. Then, the FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was added thereto and the cells were incubated and washed again. Subsequently, the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

[0113]

Since the single-chain Fv of antibody MABL-2 was specifically bound to L1210 cells expressing human IAP, it is confirmed that the reconstructed single-chain Fv of antibody MABL-2 has an affinity to human Integrin Associated Protein (IAP) (see Figures 8-11).

[0114]

#### 5.6 Competitive ELISA

The binding activity of the reconstructed single-chain Fv of antibody MABL-2 was measured based on the inhibiting activity against the binding of mouse monoclonal antibodies to the antigen.

[0115]

The anti-FLAG antibody adjusted to 1 µg/ml was added to each well on 96-well plate and incubated at 37°C for 2 hours. After washing, blocking was performed with 1% BSA-PBS. After incubating and washing at a room temperature, the culture supernatant of COS7 cells into which the secretion-type human IAP antigen gene (SEQ ID No. 26) had been introduced was diluted with PBS into twofold volume and added to each well. After incubating and washing at a room temperature, a mixture of 50 µl of the biotinized MABL-2 antibody adjusted to 100 ng/ml and 50 µl of sequentially diluted supernatant of the COS7 cells expressing the reconstructed single-chain Fv of antibody MABL-2 were added into each well. After incubating and washing at a room temperature, the alkaline phosphatase-conjugated streptoavidin (Zymed) was added into each well. After incubating and washing at a room temperature, the substrate solution (SIGMA) was added and absorbance of the reaction mixture in each well was measured at 405 nm.

[0116]

The results revealed that the reconstructed single-chain Fv of antibody MABL-2 (MABL2-scFv) evidently inhibited concentration-dependently the binding of the mouse antibody MABL-2 to human IAP antigen in comparison with the culture supernatant of the PCHO1-introduced COS7 cells as a control (Figure 12). Accordingly, it is suggested that the reconstructed single-chain Fv of antibody MABL-2 has the

correct structure of each of the V regions from the mouse monoclonal antibody MABL-2.

[0117]

#### 5.7 Apoptosis-inducing Effect in vitro

5 An apoptosis-inducing action of the reconstructed single-chain Fv of antibody MABL-2 was examined by Annexin-V staining (Boehringer Mannheim) using the L1210 cells transfected with human IAP gene, the L1210 cells transfected with the pCOS1 vector as a control and CCRF-CEM cells.

10 [0118]

To each  $1 \times 10^5$  cells of the above cells was added the culture supernatant of the COS7 cells expressing the reconstructed single-chain Fv of antibody MABL-2 or the culture supernatant of COS7 cells transfected with the pCHO1 vector as a control at 50% final concentration and the mixtures were cultured for 24 hours. Then, the Annexin-V staining was performed and the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

15 [0119]

20 Results of the Annexin-V staining are shown in Figures 13-18, respectively. Dots in the left-lower region represent living cells and dots in the right-lower region represent cells at the early stage of apoptosis and dots in the right-upper region represent cells at the late stage of apoptosis. The results show that the reconstructed single-chain Fv of antibody MABL-2 (MABL2-scFv) remarkably induced cell death of L1210 cells specific to human IAP antigen

25

(Figures 13-16) and that the reconstructed single-chain Fv also induced remarkable cell death of CCRF-CEM cells in comparison with the control (Figures 17-18).

[0120]

5       5.8 Expression of MABL-2 derived single-chain Fv in CHO cells

CHO cells were transfected with the pCHOM2 vector to establish a CHO cell line which constantly expresses the single-chain Fv (polypeptide) derived from the antibody  
10       MABL-2.

CHO cells were transformed with the pCHOM2 vector by the electroporation using the Gene Pulser apparatus (BioRad). A mixture of DNA (10 µg) and 0.7 ml of PBS with CHO cells ( $1 \times 10^7$  cells/ml) was added to a cuvette. The mixture was treated with pulse at 1.5 kV, 25 µF of electric capacity. After the restoration for 10 minutes at a room temperature, the electroporated cells were transferred into nucleic acid free α-MEM medium (GIBCO BRL) containing 10% fetal bovine serum and cultured. The expression of desired protein in the resultant clones was confirmed by SDS-PAGE  
15       and a clone with a high expression level was selected as a cell line producing the single-chain Fv derived from the antibody MABL-2. The cell line was cultured in serum free medium CHO-S-SFM II (GIBCO BRL) containing 10 nM methotrexate (SIGMA). Then, the culture supernatant was  
20       collected, centrifuged to remove cell fragments and recovered.  
25

[0121]

5.9 Purification of MABL-2 derived single-chain Fv produced  
in CHO cells

The culture supernatant of the CHO cell line expressing the single-chain Fv obtained in Example 5.8 was concentrated up to twenty times using a cartridge for the artificial dialysis (PAN130SF, ASAHI MEDICALS). The concentrated solution was stored at -20°C and thawed on purification.

Purification of the single-chain Fv from the culture supernatant of the CHO cells was performed using three kinds of chromatography, i.e., Blue-sepharose, a hydroxyapatite and a gel filtration.

[0122]

(1) Blue-sepharose column chromatography

The concentrated supernatant was diluted to ten times with 20 mM acetate buffer (pH 6.0) and centrifuged to remove insoluble materials ( $10000 \times \text{rpm}$ , 30 minutes). The supernatant was applied onto a Blue-sepharose column (20 ml) equilibrated with the same buffer. After washing the column with the same buffer, proteins adsorbed in the column were eluted by a stepwide gradient of NaCl in the same buffer, 0.1, 0.2, 0.3, 0.5 and up to 1.0 M. The pass-through fraction and each eluted fraction were analyzed by SDS-PAGE. The fractions in which the single-chain Fv were confirmed (the fractions eluted at 0.1 to 0.3M NaCl) were pooled and

concentrated up to approximately 20 times using CentriPrep-10 (AMICON).

[0123]

(2) Hydroxyapatite

5           The concentrated solution obtained in (1) was diluted to 10 times with 10 mM phosphate buffer (pH 7.0) and applied onto the hydroxyapatite column (20 ml, BIORAD). The column was washed with 60 ml of 10 mM phosphate buffer (pH 7.0). Then, proteins adsorbed in the column were eluted by a  
10 linear gradient of sodium phosphate buffer up to 200 mM (see Figure 19). The analysis of each fraction by SDS-PAGE confirmed the single-chain Fv in fraction A and fraction B.

[0124]

(3) Gel filtration

15           Each of fractions A and B in (2) was separately concentrated with CentriPrep-10 and applied onto TSKgel G3000SWG column (21.5 × 600 mm) equilibrated with 20 mM acetate buffer (pH 6.0) containing 0.15 M NaCl.  
20           Chromatograms are shown in Figure 20. The analysis of the fractions by SDS-PAGE confirmed that both major peaks (AI and BI) are of desired single-chain Fv. In the gel filtration analysis, the fraction A was eluted at 36 kDa of apparent molecular weight and the fraction B was eluted at 76 kDa. The purified single-chain Fvs (AI, BI) were analyzed  
25           with 15% SDS polyacrylamide gel. Samples were treated in the absence or presence of a reductant and the electrophoresis was carried out in accordance with the Laemmli's method.

Then the protein was stained with Coomassie Brilliant Blue. As shown in Figure 21, both AI and BI gave a single band at 35 kDa of apparent molecular weight, regardless of the absence or presence of the reductant. From the above, it is 5 concluded that AI is a monomer of the single-chain Fv and BI is a non-covalently bound dimer of the single-chain Fv. The gel filtration analysis of the fractions AI and BI with TSKgel G3000SW column (7.5 × 60 mm) revealed that a peak of the monomer is detected only in the fraction AI and a peak 10 of the dimer is detected only in the fraction BI (Figure 22).

[0125]

5.10 Construction of vector expressing single-chain Fv derived from antibody MABL-2 in E. coli cell

15 The pscM2 vector was modified by the PCR method to prepare a vector effectively expressing the single-chain Fv from the antibody MABL-2 in E. coli cells. The resultant DNA fragment was introduced into pSCFVT7 expression vector.

[0126]

20 As a forward primer for PCR, Nde-VHSm02 primer shown in SEQ ID No. 27 was designed to hybridize to a DNA encoding the N-terminal of the H chain V region and to contain a start codon and NdeI restriction enzyme recognition site. As a reverse primer for PCR, VLAS primer 25 shown in SEQ ID No. 28 was designed to hybridize to a DNA encoding the C-terminal of the L chain V region and to contain two stop codons and EcoRI restriction enzyme

recognition site. The forward primer, Nde-VHSm02, comprises five point mutations in the part hybridizing to the DNA encoding the N-terminal of the H chain V region for the effective expression in E. coli.

5 [0127]

100 µl of a PCR solution comprising 10 µl of 10 × PCR Buffer #1, 1 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, 5 units of KOD DNA polymerase (all from TOYOBO), 1 µM of each primer and 100 ng of a template DNA (pscM2) was heated at 98°C for 15 seconds, 10 at 65°C for 2 seconds and at 74°C for 30 seconds in order. This temperature cycle was repeated 25 times.

[0128]

15 The PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and digested by NdeI and EcoRI, and then the resulting DNA fragment was cloned into pSCFVT7 vector, from which pelB signal sequence had been eliminated by the digestion with NdeI and EcoRI. After DNA sequencing, the resulting plasmid comprising a DNA fragment with the desired DNA sequence is designated as "pscM2DEm02" 20 (see Figure 23). The nucleotide sequence and the amino acid sequence of the single-chain Fv derived from the antibody MABL-2 contained in the plasmid pscM2DEm02 are shown in SEQ ID No. 29.

[0129]

25 5.11 Expression of single-chain Fv derived from antibody MABL-2 in E. coli cells

E. coli BL21(DE3)pLysS (STRATAGENE) was transformed with pscM2DEm02 vector to obtain a strain of E. coli expressing the single-chain Fv derived from antibody MABL-2. The resulting clones were examined for the expression of the desired protein using SDS-PAGE, and a clone with a high expression level was selected as a strain producing the single-chain Fv derived from antibody MABL-2.

5 [0130]

5.12 Purification of single-chain Fv derived from antibody MABL-2 produced in E.coli

A single colony of E. coli obtained by the transformation was cultured in 3 ml of LB medium at 28°C for 7 hours and then in 70 ml of LB medium at 28°C overnight. This pre-culture was transplanted to 7 L of LB medium and cultured at 28°C with stirring at 300 rpm using the Jar-fermenter. When an absorbance of the medium reached O.D.=1.5, the bacteria were induced with 1 mM IPTG and then cultured for 3 hours.

15 [0131]

The culture medium was centrifuged (10000 × g, 10 minutes) and the precipitated bacteria were recovered. To the bacteria was added 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM EDTA, 0.1 M NaCl and 1% Triton X-100 and the bacteria were disrupted by ultrasonication (out put: 4, duty cycle: 70%, 1 minute × 10 times). The suspension of disrupted bacteria was centrifuged (12000 × g, 10 minutes) to precipitate inclusion body. Isolated inclusion body was

mixed with 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM EDTA, 0.1 M NaCl and 4% Triton X-100, treated by ultrasonication (out put: 4, duty cycle: 50%, 30 seconds × 2 times) again and centrifuged (12000 × g, 10 minutes) to isolate the desired protein as precipitate and to remove containment proteins included in the supernatant.

5 [0132]

The inclusion body comprising the desired protein was lysed in 50 mM Tris-HCl buffer (pH 8.0) containing 6 M Urea, 5 mM EDTA and 0.1 M NaCl and applied onto Sephadryl S-10 300 gel filtration column (5 × 90 cm, Amersham Pharmacia) equilibrated with 50 mM Tris-HCl buffer (pH 8.0) containing 4M Urea, 5 mM EDTA, 0.1 M NaCl and 10 mM mercaptoethanol at a flow rate of 5 ml/minutes to remove associated single chain Fvs with high-molecular weight. The obtained fractions were analyzed with SDS-PAGE and the fractions with high purity of the protein were diluted with the buffer used in the gel filtration up to O.D<sub>280</sub>=0.25. Then, the fractions were dialyzed three times against 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM EDTA, 0.1 M NaCl, 0.5 M Arg, 2 mM glutathione in the reduced form and 0.2 mM glutathione in the oxidized form in order for the protein to be refolded. Further, the fraction was dialyzed three times against 20 mM acetate buffer (pH 6.0) containing 0.15 M NaCl to exchange 25 the buffer.

[0133]

The dialysate product was applied onto Superdex  
200 pg gel filtration column (2.6 x 60 cm, Amersham  
Pharmacia) equilibrated with 20 mM acetate buffer (pH 6.0)  
containing 0.15 M NaCl to remove a small amount of high  
5 molecular weight protein which was intermolecularly  
crosslinked by S-S bonds. As shown in Figure 24, two peaks,  
major and sub peaks, were eluted after broad peaks which are  
expectedly attributed to an aggregate with a high molecular  
weight. The analysis by SDS-PAGE (see Figure 21) and the  
10 elution positions of the two peaks in the gel filtration  
analysis suggest that the major peak is of the monomer of  
the single-chain Fv and the sub peak is of the non-  
covalently bound dimer of the single-chain Fv. The non-  
covalently bound dimer accounted for 4 percent of total  
15 single-chain Fvs.

[0134]

5.13 Apoptosis-inducing activity in vitro of single-chain Fv  
derived from antibody MABL-2

An apoptosis-inducing action of the single-chain  
20 Fv from antibody MABL-2 (MABL2-scFv) produced by the CHO  
cells and E. coli was examined according to two protocols by  
Annexin-V staining (Boehringer Mannheim) using the L1210  
cells (hIAP/L1210) into which human IAP gene had been  
introduced.

25 In the first protocol sample antibodies at the  
final concentration of 3 µg/ml were added to  $5 \times 10^4$  cells  
of hIAP/L1210 cell line and cultured for 24 hours. Sample

antibodies, i.e., the monomer and the dimer of the single-chain Fv of MABL-2 from the CHO cells obtained in Example 5.9, the monomer and the dimer of the single-chain Fv of MABL-2 from E. coli obtained in Example 5.12, and the mouse IgG antibody as a control were analyzed. After culturing, the Annexin-V staining was carried out and the fluorescence intensity thereof was measured using the FACScan apparatus (BECTON DICKINSON).

In the second protocol sample antibodies at the final concentration of 3 µg/ml were added to  $5 \times 10^4$  cells of hIAP/L1210 cell line, cultured for 2 hours and mixed with anti-FLAG antibody (SIGMA) at the final concentration of 15 µg/ml and further cultured for 22 hours. Sample antibodies of the monomer of the single-chain Fv of MABL-2 from the CHO cells obtained in Example 5.9 and the mouse IgG antibody as a control were analyzed. After culturing, the Annexin-V staining was carried out and the fluorescence intensity thereof was measured using the FACScan apparatus.

Results of the analysis by the Annexin-V staining are shown in Figures 25-31. The results show that the dimers of the single-chain Fv polypeptide of MABL-2 produced in the CHO cells and E. coli remarkably induced cell death (Figures 26, 27) in comparison with the control (Figure 25), while no apoptosis-inducing action was observed in the monomers of the single-chain Fv polypeptide of MABL-2 produced in the CHO cells and E. coli (Figures 28, 29). When anti-FLAG antibody was used together, the monomer of the single-chain

Fv polypeptide derived from antibody MABL-2 produced in the CHO cells induced remarkably cell death (Figure 31) in comparison with the control (Figure 30).

[0135]

5       5.14 Antitumor effect of the monomer and the dimer of scFv/CHO polypeptide with a model mouse of human myeloma

(1) Quantitative measurement of human IgG in mouse serum

Measurement of human IgG (M protein) produced by human myeloma cell and contained in mouse serum was carried out by the following ELISA. 100 µL of goat anti-human IgG antibody (BIOSOURCE, Lot#7902) diluted to 1 µg/mL with 0.1% bicarbonate buffer (pH 9.6) was added to each well on 96 wells plate (Nunc) and incubated at 4°C overnight so that the antibody was immobilized. After blocking, 100 µL of the stepwisely diluted mouse serum or human IgG (CAPPYEL, Lot#00915) as a standard was added to each well and incubated for 2 hours at a room temperature. After washing, 100 µL of alkaline phosphatase-labeled anti-human IgG antibody (BIOSOURCE, Lot#6202) which had been diluted to 5000 times was added, and incubation was carried out for 1 hour at a room temperature. After washing, a substrate solution was added. After incubation, absorbance at 405 nm was measured using the MICROPLATE READER Model 3550 (BioRad). The concentration of human IgG in the mouse serum was calculated based on the calibration curve obtained from the absorbance values of human IgG as the standard.

[0136]

(2) Preparation of antibodies for administration

The monomer and the dimer of the scFv/CHO polypeptide were respectively diluted to 0.4 mg/mL or 0.25 mg/mL with sterile filtered PBS(-) on the day of administration to prepare samples for the administration.

5

[0137]

(3) Preparation of a mouse model of human myeloma

A mouse model of human myeloma was prepared as follows. KPMM2 cells passaged in vivo (JP-Appl. 7-236475) by SCID mouse (Japan Clare) were suspended in RPMI1640 medium (GIBCO-BRL) containing 10% fetal bovine serum (GIBCO-BRL) and adjusted to  $3 \times 10^7$  cells/mL. 200  $\mu$ L of the KPMM2 cell suspension ( $6 \times 10^6$  cells/mouse) was transplanted to the SCID mouse (male, 6 week-old) via caudal vein thereof, which had been subcutaneously injected with the asialo GM1 antibody (WAKO JUNYAKU, 1 vial dissolved in 5 mL) a day before the transplantation.

10  
15 [0138]

(4) Administration of antibodies

The samples of the antibodies prepared in (2), the monomer (250  $\mu$ L) and the dimer (400  $\mu$ L), were administered to the model mice of human myeloma prepared in (3) via caudal vein thereof. The administration was started from three days after the transplantation of KPMM2 cells and was carried out twice a day for three days. As a control, 200  $\mu$ L of sterile filtered PBS(-) was likewise administered twice a

20

25

day for three days via caudal vein. Each group consisted of seven mice.

[0139]

5           (5) Evaluation of antitumor effect of the monomer and the dimer of scFv/CHO polypeptide with the model mouse of human myeloma

The antitumor effect of the monomer and the dimer of scFv/CHO polypeptide with the model mice of human myeloma was evaluated in terms of the change of human IgG (M protein) concentration in the mouse serum and survival time of the mice. The change of human IgG concentration was determined by measuring it in the mouse serum collected at 24 days after the transplantation of KPMM2 cells by ELISA described in the above (1). The amount of serum human IgG (M protein) in the serum of the PBS(-)-administered group (control) increased to about 8500 µg/mL, whereas the amount of human IgG of the scFv/CHO dimer-administered group was remarkably low, that is, as low as one-tenth or less than that of the control group. Thus, the results show that the dimer of scFv/CHO strongly inhibits the growth of the KPMM2 cells (Figure 32). As shown in Figure 33, a remarkable elongation of the survival time was observed in the scFv/CHO dimer-administered group in comparison with the PBS(-)-administered group.

25           [0140]

From the above, it is confirmed that the dimer of scFv/CHO has an antitumor effect for the human myeloma model

mice. It is considered that the antitumor effect of the dimer of scFv/CHO, the reconstructed polypeptide of the invention, results from the apoptosis-inducing action of the reconstructed polypeptide.

5 [0141]

#### 5.15 Hemagglutination Test

Hemagglutination test and determination of hemagglutination were carried out in accordance with "Immuno-Biochemical Investigation", Zoku-Seikagaku Jikken Koza, edited by the Biochemical Society of Japan, published by Tokyo Kagaku Dojin.

Blood was taken from a healthy donor using heparin-treated syringes and washed with PBS(-) three times, and then erythrocyte suspension with a final concentration of 2% in PBS(-) was prepared. Test samples were the antibody MABL-2, the monomer and the dimer of the single-chain Fv polypeptide produced by the CHO cells, and the monomer and the dimer of the single-chain Fv polypeptide produced by E. coli, and the control was mouse IgG (ZYMED). For the investigation of the hemagglutination effect, round bottom 96-well plates available from Falcon were used. 50 µL per well of the aforementioned antibody samples and 50 µL of the 2% erythrocyte suspension were added and mixed in the well. After incubation for 2 hours at 37°C, the reaction mixtures were stored at 4°C overnight and the hemagglutination thereof was determined. As a control, 50 µL per well of PBS(-) was used and the hemagglutination test was carried

out in the same manner. The mouse IgG and antibody MABL-2  
were employed at 0.01, 0.1, 1.0, 10.0 or 100.0 µg/mL of the  
final concentration of the antibodies. The single-chain Fvs  
were employed at 0.004, 0.04, 0.4, 4.0, 40.0 or 80.0 µg/mL  
of the final concentration and further at 160.0 µg/mL only  
in the case of the dimer of the polypeptide produced by E.  
coli. Results are shown in the Table 2. In the case of  
antibody MABL-2, the hemagglutination was observed at a  
concentration of more than 0.1 µg/mL, whereas no  
hemagglutination was observed for both the monomer and the  
dimer of the single-chain Fv.

10 [0142]

Table 2 **Hemagglutination Test**

	Control	0.01	0.1	1	10	100	μg/mL
mIgG	-	-	-	-	-	-	
MABL-2 (intact)	-	-	+	+++	+++	++	
	Control	0.004	0.04	0.4	4	40	μg/mL
scFv/CHO monomer	-	-	-	-	-	-	
scFv/CHO dimer	-	-	-	-	-	-	
	Control	0.004	0.04	0.4	4	40	160 μg/mL
scFv/E.coli monomer	-	-	-	-	-	-	
scFv/E.coli dimer	-	-	-	-	-	-	

[0143]

Example 6 Reconstructed polypeptide sc(Fv)<sub>2</sub> comprising two H chain V regions and two L chain V regions and antibody MABL-2 scFvs having linkers with different length

6.1 Construction of Plasmid expressing antibody MABL-2

sc(Fv)<sub>2</sub>

For the preparation of a plasmid expressing the reconstructed polypeptide [sc(Fv)<sub>2</sub>] which comprises two H chain V regions and two L chain V regions derived from the antibody MABL-2, the aforementioned pCHOM2, which comprises the DNA encoding scFv derived from the MABL-2 described above, was modified by the PCR method as mentioned below and the resulting DNA fragment was introduced into pCHOM2.

Primers employed for the PCR are EF1 primer (SEQ ID NO: 30) as a sense primer, which is designed to hybridize to a DNA encoding EF1 $\alpha$ , and an antisense primer (SEQ ID NO: 19), which is designed to hybridize to the DNA encoding C-terminal of the L chain V region and to contain a DNA sequence coding for a linker region, and VLLAS primer containing SalI restriction enzyme recognition site (SEQ ID NO 31).

[0144]

100  $\mu$ l of the PCR solution comprises 10  $\mu$ l of 10  $\times$  PCR Buffer #1, 1 mM MgCl<sub>2</sub>, 0.2 mM dNTPs (dATP, dGTP, dCTP and dTTP), 5 units of KOD DNA polymerase (Toyobo, Inc.), 1  $\mu$ M of each primer and 100 ng of the template DNA (pCHOM2). The PCR solution was heated at 94°C for 30 seconds, at 50°C for 30 seconds and at 74°C for 1 minute in order. This temperature cycle was repeated 30 times.

[0145]

The PCR product was purified using the QIAquick PCR Purification Kit (QIAGEN) and digested by SalI. The resultant DNA fragment was cloned into pBluescript KS<sup>+</sup> vector (Toyobo, Inc.). After DNA sequencing, a plasmid comprising the desired DNA sequence was digested by SalI and the obtained DNA fragment was connected using Rapid DNA Ligation Kit (BOEHRINGER MANNHEIM) to pCHOM2 digested by SalI. After DNA sequencing, a plasmid comprising the desired DNA sequence is designated as "pCHOM2(Fv)<sub>2</sub>" (see Figure 34). The nucleotide sequence and the amino acid sequence of the

antibody MABL-2 sc(Fv)<sub>2</sub> region contained in the plasmid pCHOM2(Fv)<sub>2</sub> are shown in SEQ ID No. 32.

[0146]

6.2 Preparation of Plasmid expressing antibody MABL-2 scFvs having linkers with various length

The scFvs containing linkers with different length and the V regions which are designed in the order of [H chain]-[L chain] (hereinafter "HL") or [L chain]-[H chain] (hereinafter "LH") were prepared using, as a template, cDNAs encoding the H chain and the L chain derived from the MABL-2 as mentioned below.

[0147]

To construct HL type scFv the PCR procedure was carried out using pCHOM2(Fv)<sub>2</sub> as a template. In the PCR step, a pair of CFHL-F1 primer (SEQ ID NO: 33) and CFHL-R2 primer (SEQ ID NO: 34) or a pair of CFHL-F2 primer (SEQ ID NO: 35) and CFHL-R1 primer (SEQ ID NO: 36) and KOD polymerase were employed. The PCR procedure was carried out by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order to produce a cDNA for the H chain containing a leader sequence at 5'-end or a cDNA for the L chain containing FLAG sequence at 3'-end thereof. The resultant cDNAs for the H chain and the L chain were mixed and PCR was carried out by repeating 5 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order using the mixture as templates

and the KOD polymerase. To the reaction mixture were added CFHL-F1 and CFHL-R1 primers and then the PCR reaction was performed by repeating 30 times of the aforementioned temperature cycle to produce a cDNA for HL-0 type without a  
5 linker.

[0148]

To construct LH type scFv, the PCR reaction was carried out using, as a template, pGEM-M2L and pGEM-M2H which contain cDNAs encoding the L chain V region and the H  
10 chain V region from the antibody MABL-2, respectively (see JP- Appl. 11-63557). A pair of T7 primer (SEQ ID NO: 37) and CFLH-R2 primer(SEQ ID NO: 38) or a pair of CFLH-F2 primer (SEQ ID NO: 39) and CFLH-R1 (SEQ ID NO: 40) and the KOD polymerase (Toyobo Inc.) were employed. The PCR reaction was  
15 performed by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in sequential order to produce a cDNA of an L chain containing a leader sequence at 5'-end or a cDNA of an H chain containing FLAG sequence at 3'-end thereof.  
The resultant cDNAs of the L chain and the H chain were  
20 mixed and PCR was carried out using this mixture as templates and the KOD polymerase by repeating 5 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order. To the  
25 reaction mixture were added T7 and CFLH-R1 primers and the reaction was performed by repeating 30 times of the aforementioned temperature cycle. The reaction product was

used as a template and PCR was carried out using a pair of CFLH-F4 primer (SEQ ID NO: 41) and CFLH-R1 primer by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order to produce a cDNA of LH-0 type without a linker.

5 [0149]

The resultant cDNAs of LH-0 and HL-0 types were digested by EcoRI and BamHI restriction enzymes (Takara Shuzo) and the digested cDNAs were introduced into an expression plasmid INPEP4 for mammalian cells using Ligation High (Toyobo Inc.), respectively. Competent E. coli JM109 (Nippon Gene) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using QIAGEN Plasmid Maxi Kit (QIAGEN). Thus plasmids pCF2LH-0 and pCF2HL-0 were prepared.

15 [0150]

To construct the expression plasmids of HL type containing linkers with different size, pCF2HL-0, as a template, and CFHL-X3 (SEQ ID NO: 42), CFHL-X4 (SEQ ID NO: 43), CFHL-X5 (SEQ ID NO: 44), CFHL-X6 (SEQ ID NO: 45) or CFHL-X7 (SEQ ID NO: 46), as a sense primer, and BGH-1 (SEQ ID NO: 47) primer, as an antisense primer, which is complementary with the vector sequence were employed. PCR reaction was carried out using the KOD polymerase by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order and the reaction products were digested by restriction

enzymes XhoI and BamHI (Takara Shuzo). The digested  
fragments were introduced between XhoI and BamHI sites in  
the pCF2HL-0 using Ligation High (Toyobo Inc.),  
respectively. Competent E. coli JM109 was transformed with  
5 each plasmid and the desired plasmids were isolated from the  
transformed E. coli by using Qiagen Plasmid Maxi kit. Thus  
expression plasmids pCF2HL-3, pCF2HL-4, pCF2HL-5, pCF2HL-6  
and pCF2HL-7 were prepared.

To construct expression plasmid for the transient  
10 expression in COS7 cells the plasmids pCF2HL-0, pCF2HL-3,  
pCF2HL-4, pCF2HL-5, pCF2HL-6 and pCF2HL-7 were digested by  
restriction enzymes EcoRI and BamHI (Takara Shuzo) and the  
resultant fragments of approximately 800 bp were purified  
with agarose gel electrophoresis. The obtained fragments  
15 were introduced between EcoRI and BamHI sites in an  
expression plasmid pCOS1 for the expression in mammalian  
cells by using Ligation High (Toyobo Inc.), respectively.  
Competent E. coli DH5 $\alpha$  (Toyobo Inc.) was transformed with  
each plasmid and the desired plasmids were isolated from the  
20 transformed E. coli using Qiagen Plasmid Maxi kit. Thus the  
expression plasmids CF2HL-0/pCOS1, CF2HL-3/pCOS1, CF2HL-  
4/pCOS1, CF2HL-5/pCOS1, CF2HL-6/pCOS1 and CF2HL-7/pCOS1 were  
prepared.

As a typical example of these plasmids, the  
25 construction of the plasmid CF2HL-0/pCOS1 is illustrated in  
Figure 35 and the nucleotide sequence and the amino acid  
sequence of MABL2-scFv <HL-0> contained in the plasmid are

shown in SEQ ID No. 48. Nucleotide sequences and amino acid sequences of the linker regions in these plasmids are also shown in Figure 36.

[0151]

5 To construct the expression plasmids of LH type containing linkers with different size, pCF2LH-0, as a template, and CFLH-X3 (SEQ ID NO: 49), CFLH-X4 (SEQ ID NO: 50), CFLH-X5 (SEQ ID NO: 51), CFLH-X6 (SEQ ID NO: 52) or CFLH-X7 (SEQ ID NO: 53), as a sense primer, and BGH-1  
10 primer, as an antisense primer, which is complementary with the vector sequence were employed. PCR reaction was carried out using the KOD polymerase by repeating 30 times the temperature cycle consisting of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in order and the  
15 reaction products were digested by restriction enzymes XhoI and BamHI. The digested fragments were introduced into the pCF2LH-0 between XhoI and BamHI sites using Ligation High, respectively. Competent E. coli DH5 $\alpha$  (Toyobo Inc.) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using Qiagen Plasmid Maxi kit. Thus expression plasmids pCF2LH-3, pCF2LH-4,  
20 pCF2LH-5, pCF2LH-6 and pCF2LH-7 were prepared.

To construct expression plasmid for the transient expression in COS7 cells the plasmids pCF2LH-0, pCF2LH-3, pCF2LH-4, pCF2LH-5, pCF2LH-6 and pCF2LH-7 were digested by restriction enzymes EcoRI and BamHI (Takara Shuzo) and the resultant fragments of approximately 800 bp were purified  
25

with agarose gel electrophoresis. The obtained fragments were introduced between XhoI and BamHI sites in an expression plasmid pCOS1 for the expression in mammalian cells by using the Ligation High, respectively. Competent E. coli DH5 $\alpha$  (Toyobo Inc.) was transformed with each plasmid and the desired plasmids were isolated from the transformed E. coli using the Qiagen Plasmid Maxi kit. Consequently, the expression plasmids CF2LH-0/pCOS1, CF2LH-3/pCOS1, CF2LH-4/pCOS1, CF2LH-5/pCOS1, CF2LH-6/pCOS1 and CF2LH-7/pCOS1 were prepared.

As a typical example of these plasmids, the construction of the plasmid CF2LH-0/pCOS1 is illustrated in Figure 37 and the nucleotide sequence and the amino acid sequence of MABL2-scFv <LH-0> contained in the plasmid are shown in SEQ ID No. 54. Nucleotide sequences and amino acid sequences of the linker regions in these plasmids are also shown in Figure 38.

[0152]

### 6.3 Expression of scFvs and sc(Fv)<sub>2</sub> in COS7 cells

(1) Preparation of culture supernatant using serum-containing culture medium

The HL type and LH type of scFvs and sc(Fv)<sub>2</sub> were transiently expressed in COS7 cells (JCRB9127, Japan Health Sciences Foundation). COS7 cells were subcultured in DMEM media (GIBCO BRL) containing 10% fetal bovine serum (HyClone) at 37°C in carbon dioxide atmosphere incubator.

[0153]

The COS7 cells were transfected with CF2HL-0, 3 ~ 7/pCOS1, or CF2LH-0, 3 ~ 7/pCOS1 prepared in Example 6.2 or pCHOM2 (Fv)<sub>2</sub> vectors by electroporation using the Gene Pulser apparatus (BioRad). The DNA (10 µg) and 0.25 ml of  $2 \times 10^7$  cells/ml in DMEM culture medium containing 10% FBS and 5 mM BES (SIGMA) were added to a cuvette. After standing for 10 minutes the mixtures were treated with pulse at 0.17kV, 950µF of electric capacity. After the restoration for 10 minutes at room temperature, the electroporated cells were transferred into the DMEM culture medium (10%FBS) in 75 cm<sup>3</sup> flask. After culturing for 72 hours, the culture supernatant was collected and centrifuged to remove cell fragments. The culture supernatant was subjected to the filtration using 0.22 µm bottle top filter (FALCON) to obtain the culture supernatant (hereinafter "CM").

[0154]

(2) Preparation of culture supernatant using serum-free culture medium

Cells transfected in the same manner as (1) were transferred to the DMEM medium (10% FBS) in 75 cm<sup>3</sup> flask and cultured overnight. After the culture, the supernatant was discarded and the cells were washed with PBS and then added to CHO-S-SFM II medium (GIBCO BRL). After culturing for 72 hours, the culture supernatant was collected, centrifuged to remove cell fragments and filtered using 0.22 µm bottle top filter (FALCON) to obtain CM.

[0155]

#### 6.4 Detection of scFvs and sc(Fv)<sub>2</sub> in CM of COS7

The various MABL2-scFVs and sc(Fv)<sub>2</sub> in CM of COS7 prepared in the aforementioned Example 6.3 (2) were detected by Western Blotting method.

5           Each CM of COS7 was subjected to SDS-PAGE electrophoresis and transferred to REINFORCED NC membrane (Schleicher & Schuell). The membrane was blocked with 5% skim milk (Morinaga Nyu-gyo) and washed with TBS. Then an anti-FLAG antibody (SIGMA) was added thereto. The membrane  
10          was incubated at room temperature and washed. A peroxidase labeled mouse IgG antibody (Jackson Immuno Research) was added. After incubating and washing at room temperature, the substrate solution (Kirkegaard Perry Laboratories) was added to develop color (Figure 39).

15          [0156]

#### 6.5 Flow cytometry

Flow cytometry was performed using the culture supernatants of COS7 cells prepared in Example 6.3 (1) to measure the binding of the MABL2-scFVs and sc(Fv)<sub>2</sub> to human Integrin Associated Protein (IAP) antigen. The culture supernatants to be tested or a culture supernatant of COS7 cells as a control was added to  $2 \times 10^5$  cells of the mouse leukemia cell line L1210 expressing human IAP. After incubating on ice and washing, 10 µg/mL of the mouse anti-FLAG antibody (SIGMA) was added and then the cells were incubated and washed. Then, the FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was added thereto and the cells

were incubated and washed again. The fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

[0157]

The results of the flow cytometry show that the  
5 MABL2-scFvs having linkers with different length and the sc(Fv)<sub>2</sub> in the culture supernatants of COS7 have high affinity to human IAP (see Figure 40).

[0158]

#### 6.6 Apoptosis-inducing Effect in vitro

An apoptosis-inducing action of the culture supernatants of COS7 prepared in Example 6.3 (1) was examined by Annexin-V staining (Boehringer Mannheim) using the L1210 cells transfected with human IAP gene (hIAP/L1210).

To  $5 \times 10^4$  cells of the hIAP/L1210 cells were added the culture supernatants of COS7 cells transfected with each vectors or a culture supernatant of COS7 cells as a control at 10% of the final concentration and the mixtures were cultured for 24 hours. Then, the Annexin-V/PI staining was performed and the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON). The results revealed that scFvs <HL3, 4, 6, 7, LH3, 4, 6, 7> and sc(Fv)<sub>2</sub> in CM of COS7 induced remarkable cell death of hIAP/L1210 cells. These results are shown in Figure 41.

[0159]

#### 6.7 Construction of vectors for the expression of scFvs and sc(Fv)<sub>2</sub> in CHO cells

To isolate and purify MABL2-scFvs and sc(Fv)<sub>2</sub> from culture supernatant, the expression vectors for expressing in CHO cells were constructed as below.

The EcoRI-BamHI fragments of pCF2HL-0, 3 ~ 7, and pCF2LH-0, 3 ~ 7 prepared in Example 6.2 were introduced between EcoRI and BamHI sites in an expression vector pCHO1 for CHO cells using the Ligation High. Competent E. coli DH5 $\alpha$  was transformed with them. The plasmids were isolated from the transformed E. coli using QIAGEN Plasmid Midi kit (QIAGEN) to prepare expression plasmids pCHOM2HL-0, 3 ~ 7, and pCHOM2LH-0, 3 ~ 7.

[0160]

6.8 Production of CHO cells expressing MABL2-scFvs <HL-0, 3 ~ 7>, MABL2-scFvs <LH-0, 3 ~ 7> and sc(Fv)<sub>2</sub> and preparation of the culture supernatants thereof

CHO cells were transformed with each of the expression plasmids pCHOM2HL-0, 3 ~ 7, and pCHOM2LH-0, 3 ~ 7, constructed in Example 6.7 and pCHOM2(Fv)<sub>2</sub> vector to prepare the CHO cells constantly expressing each reconstructed polypeptide. As a typical example thereof, the production of the CHO cells constantly expressing MABL2-scFv <HL-5> or sc(Fv)<sub>2</sub> is illustrated as follows.

[0161]

The expression plasmids pCHOM2HL-5 and pCHOM2(Fv)<sub>2</sub> were linearized by digesting with a restriction enzyme PvuI and subjected to transfection to CHO cells by electroporation using Gene Pulser apparatus (BioRad). The

DNA (10 µg) and 0.75 ml of PBS with  $1 \times 10^7$  cells/ml were added to a cuvette and treated with pulse at 1.5 kV, 25 µF of electric capacity. After the restoration for 10 minutes at room temperature, the electroporated cells were transferred into nucleic acid-containing α-MEM culture medium (GIBCO BRL) containing 10% fetal bovine serum and cultured. After culturing overnight, the supernatant was discarded. The cells were washed with PBS and added to nucleic acid-free α-MEM culture medium (GIBCO BRL) containing 10% fetal bovine serum. After culturing for two weeks, the cells were cultured in a medium containing 10 nM (final concentration) methotrexate (SIGMA), then 50 nM and 100 nM methotrexate. The resultant cells were cultured in serum-free CHO-S-SFM II medium (GIBCO BRL) in a roller bottle. The culture supernatant was collected, centrifuged to remove cell fragments and filtered using a filter with 0.22 µm of pore size to obtain CM, respectively.

According to the above, CHO cells which constantly express MABL2-scFvs <HL-0, -3, -4, -6, -7> and <LH-0, -3, -4, -5, -6, -7> and CMs thereof were obtained.

[0162]

#### 6.9 Purification of dimer of MABL2-scFv <HL-5> and sc(Fv)<sub>2</sub>

According to Example 5.9 CMs prepared in Example 6.8 were concentrated and the MABL2-scFv <HL-5> and the sc(Fv)<sub>2</sub> were purified by three kinds of chromatography, i.e., Blue-sepharose, a hydroxyapatite and a gel filtration.

[0163]

6.10 Evaluation of the binding activity of purified dimer of scFv <HL-5> and sc(Fv)<sub>2</sub> against antigen

Flow cytometry was performed using the purified dimer of MABL2-scFv <HL-5> and the purified sc(Fv)<sub>2</sub> in order to evaluate the binding to human Integrin Associated Protein (IAP) antigen. 10 $\mu$ g/ml of the purified dimer of MABL2-scFv <HL-5>, the purified sc(Fv)<sub>2</sub>, the antibody MABL-2 as a positive control or a mouse IgG (Zymed) as a negative control was added to  $2 \times 10^5$  cells of the mouse leukemia cell line L1210 expressing human IAP (hIAP/L1210) or the cell line L1210 transformed with pCOS1 (pCOS1/L1210) as a control. After incubating on ice and washing, 10 $\mu$ g/mL of the mouse anti-FLAG antibody (SIGMA) was added and then the cells were incubated and washed. FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was added thereto and the cells were incubated and washed again. Then the fluorescence intensity was measured using the FACScan apparatus (BECTON DICKINSON).

[0164]

Since the purified dimer of MABL2-scFv <HL-5> and the purified sc(Fv)<sub>2</sub> were specifically bound to hIAP/L1210 cells, it is confirmed that the dimer of scFv <HL-5> and the sc(Fv)<sub>2</sub> have high affinity to human IAP (see Figure 42).

[0165]

6.11 Apoptosis-inducing activity in vitro of purified dimer of scFv <HL-5> and sc(Fv)<sub>2</sub>

An apoptosis-inducing action of the purified dimer of MABL2-scFv <HL-5> and the purified sc(Fv)<sub>2</sub> were examined by Annexin-V staining (Boehringer Mannheim) using the L1210 cells (hIAP/L1210) in which human IAP gene had been introduced and cells of human leukemic cell line CCRF-CEM.

5 [0166]

Different concentrations of the purified dimer of MABL2-scFv <HL-5>, the purified MABL2-sc(Fv)<sub>2</sub>, the antibody MABL-2 as a positive control or a mouse IgG as a negative control were added to  $5 \times 10^4$  cells of hIAP/L1210 cell line or  $1 \times 10^5$  cells of CCRF-CEM cell line. After culturing for 10 24 hours, the Annexin-V staining was carried out and the fluorescence intensity thereof was measured using the FACScan apparatus (BECTON DICKINSON). As a result the dimer 15 of MABL2-scFv <HL-5> and the MABL2-sc(Fv)<sub>2</sub> remarkably induced cell death of hIAP/L1210 and CCRF-CEM in concentration-dependent manner (see Figure 43).

15 [0167]

6.12 Hemagglutination Test of the purified dimer of scFv <HL-5> and the sc(Fv)<sub>2</sub>

Hemagglutination test was carried out using different concentrations of the purified dimer of scFv <HL-5> and the purified sc(Fv)<sub>2</sub> in accordance with Example 5.15.

The hemagglutination was observed with the 25 antibody MABL-2 as a positive control, whereas no hemagglutination was observed with both the single chain antibody MABL2-sc(Fv)<sub>2</sub> and the MABL2-scFv <HL-5>. Further,

there was no substantial difference in the hemagglutination between two buffers employed with the antibody MABL-2. These results are shown in Table 3.

[0168]

TABLE 3

## Hemagglutination Test

[0169]

[EFFECT OF THE INVENTION]

The reconstructed polypeptides of the invention have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination, and are useful as a therapeutic agent for blood dyscrasias, for example, leukemia such as acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia and hairy cell leukemia, malignant lymphoma (Hodgkin's disease, non-Hodgkin's lymphoma), aplastic anemia, myelodysplasia syndrome and polycythemia vera.

~~【発明の効果】~~

本発明の再構成ポリペプチドは、ヒトIAPを有する有核血液細胞にアポトーシスを誘起し、且つ赤血球凝集を起こさないという特性を有していることから、急性骨髓性白血病、慢性骨髓性白血病、~~急性~~リンパ性白血病、慢性リンパ性白血病、成人T細胞白血病、多発性骨髓腫、Mixed Leukemia、Hairy cell Leukemia等の白血病、悪性リンパ腫（Hodgkin病、非Hodgkinリンパ腫）、再生不良性貧血、骨髓異形成症候群、真性多血症などの血液疾患の治療薬として有用である。

## 【0170】

## 【配列表】

## SEQUENCE LISTING

&lt;110&gt; CHUGAI SEIYAKU KABUSHIKI KAISHA

&lt;120&gt; A polypeptide inducible apoptosis

&lt;130&gt; DOJ-5467

&lt;160&gt; 54

&lt;210&gt; 1

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 1

ccatcctaat acgactcaact ataggc 27

&lt;210&gt; 2

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> PCR primer

<400> 2

ggatcccggtt tggatggatgg gaagatg 27

<210> 3

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 3

ggatcccggtt ccagtggata gacagatg 28

<210> 4

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 4

ggatcccggtt agtggataga ccgatg 26

<210> 5

<211> 394

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)...(393)

整理番号=D O J - 5 4 6 7

提出日 平成12年10月20日  
頁： 54/ 97

&lt;223&gt; pGEM-M1L.1~57;signal peptide,58~394;mature peptide

&lt;400&gt; 5

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct	45
Met Lys Leu Pro Val Arg Leu Leu Val Met Phe Trp Ile Pro	
5 10 15	
gcg tcc agc agt gat gtt gtg atg acc caa act cca ctc tcc ctg	90
Ala Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu	
20 25 30	
cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt	135
Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser	
35 40 45	
cag agc ctt cta cac agt aaa gga aac acc tat tta caa tgg tac	180
Gln Ser Leu Leu His Ser Lys Gly Asn Thr Tyr Leu Gln Trp Tyr	
50 55 60	
cta cag aag cca ggc cag tct cca aag ctc ctg atc tac aaa gtt	225
Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val	
65 70 75	
tcc aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga	270
Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly	
80 85 90	
tca ggg aca gat ttc aca ctc aag atc agc aga gtg gag gct gag	315
Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu	
95 100 105	
gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac	360
Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr	
110 115 120	
acg tcc gga ggg ggg acc aag ctg gaa ata aaa c	394
Thr Ser Gly Gly Thr Lys Leu Glu Ile Lys	
125 130	

&lt;210&gt; 6

&lt;211&gt; 409

&lt;212&gt; DNA

&lt;213&gt; Mus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(408)

&lt;223&gt; pGEM-M1H.1~57;signal peptide,58~409;mature peptide

&lt;400&gt; 6

atg gaa tgg agc tgg ata ttt ctc ttc ctc ctg tca gga act gca 45

Met Glu Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala

5 10 15

ggt gtc cac tcc cag gtc cag ctg cag cag tct gga cct gac ctg 90

Gly Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu

20 25 30

gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga 135

Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly

35 40 45

tac acc ttc gtt aac cat gtt atg cac tgg gtg aag cag aag cca 180

Tyr Thr Phe Val Asn His Val Met His Trp Val Lys Gln Lys Pro

50 55 60

ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 225

Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp

65 70 75

ggt act aag tac aat gag aag ttc aag ggc aag gcc aca ctg act 270

Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr

80 85 90

tca gag aaa tcc tcc agc gca gcc tac atg gag ctc agc agc ctg 315

Ser Glu Lys Ser Ser Ser Ala Ala Tyr Met Glu Leu Ser Ser Leu  
 95 100 105  
 gcc tct gag gac tct gcg gtc tac tac tgt gca aga ggg ggt tac 360  
 Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr  
 110 115 120  
 tat agt tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcc 405  
 Tyr Ser Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser  
 125 130 135  
 tca g 409  
 Ser

<210> 7  
 <211> 394  
 <212> DNA  
 <213> Mus  
 <220>  
 <221> CDS  
 <222> (1)...(393)  
 <223> pGEM-M2L. 1~57;signal peptide, 58~394;mature peptide  
 <400> 7

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct 45  
 Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro  
 5 10 15  
 ggt tcc agc agt gat gtt gtg atg acc caa agt cca ctc tcc ctg 90  
 Gly Ser Ser Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu  
 20 25 30  
 cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tca agt 135  
 Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser  
 35 40 45

提出日 平成12年10月20日  
頁: 57/ 97

整理番号=D O J - 5 4 6 7

cag agc ctt gtg cac agt aat gga aag acc tat tta cat tgg tac 180

Gln Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr

50

55

60

ctg cag aag cca ggc cag tct cca aaa ctc ctg atc tac aaa gtt 225

Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val

65

70

75

tcc aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga 270

Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly

80

85

90

tca gtg aca gat ttc aca ctc atg atc agc aga gtg gag gct gag 315

Ser Val Thr Asp Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu

95

100

105

gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac 360

Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr

110

115

120

acg ttc gga ggg ggg acc aag ctg gaa ata aaa c 394

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys

125

130

<210> 8

<211> 409

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)...(408)

<223> pGEM-M2H. 1~57;signal peptide, 58~409;mature peptide

<400> 8

atg gaa tgg agc tgg ata ttt ctc ttc ctc ctg tca gga act gca 45

提出日 平成12年10月20日  
頁： 58/ 97

整理番号=D O J - 5 4 6 7

Met Glu Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala		
5	10	15
ggt gtc cac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg	90	
Gly Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu		
20	25	30
gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga	135	
Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly		
35	40	45
tac acc ttc gct aac cat gtt att cac tgg gtg aag cag aag cca	180	
Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro		
50	55	60
ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat	225	
Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp		
65	70	75
ggt act aag tat aat gag aag ttc aag gac aag gcc act ctg act	270	
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr		
80	85	90
tca gac aaa tcc tcc acc aca gcc tac atg gac ctc agc agc ctg	315	
Ser Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu		
95	100	105
gcc tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt tac	360	
Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr		
110	115	120
tat act tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcc	405	
Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser		
125	130	135
tca g		409
Ser		

整理番号=D O J - 5 4 6 7

提出日 平成12年10月20日  
頁： 59/ 97

<210> 9

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 9

cccaagcttc caccatgaag ttgcctgtta gg 32

<210> 10

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 10

cccaagcttc caccatggaa tggagctgga ta 32

<210> 11

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 11

cgcggatcca ctcacgtttt atttccagct tggt 34

<210> 12

<211> 34

整理番号=D O J - 5 4 6 7

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 12

cgccggatcca ctcacctgag gagactgtga gagt 34

<210> 13

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 13

catgccatgg cgcaggatcca gctgcagcag 30

<210> 14

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 14

accaccaccc gaggagactg tgagagt 27

<210> 15

<211> 27

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 15

gtctcctcag gtgggtgg ttcgggt 27

&lt;210&gt; 16

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 16

cacaacatcc gatccgccac cacccga 27

&lt;210&gt; 17

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 17

ggcggatcgg atgttgtat gacccaa 27

&lt;210&gt; 18

&lt;211&gt; 57

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

整理番号=D O J - 5 4 6 7

<400> 18

ccggaattct cattatttat cgtcatcgta tttgtagtct tttatttcca gcttggt 57

<210> 19

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Linker amino acid sequence and nucleotide sequence

<400> 19

ggg ggg ggg ggt tcg ggt ggt ggt tcg ggt ggt ggc gga tcg 45

Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

5

10

15

<210> 20

<211> 828

<212> DNA

<213> Mus

<220>

<221>CDS

<222>(1)...(826)

<223> pscM1. MABL1-scFv

<400> 20

atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc 45

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu

5

10

15

gct gcc caa cca gcc atg gcg cag gtc cag ctg cag cag tct gga 90

Ala Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Gln Ser Gly

20

25

30

cct gac ctg gta aag cct ggg gct tca gtg aag atg tcc tgc aag 135

Pro Asp Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys

35

40

45

gct tct gga tac acc ttc gtt aac cat gtt atg cac tgg gtg aag 180

Ala Ser Gly Tyr Thr Phe Val Asn His Val Met His Trp Val Lys

50

55

60

cag aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct 225

Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro

65

70

75

tac aat gat ggt act aag tac aat gag aag ttc aag ggc aag gcc 270

Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala

80

85

90

aca ctg act tca gag aaa tcc tcc agc gca gcc tac atg gag ctc 315

Thr Leu Thr Ser Glu Lys Ser Ser Ala Ala Tyr Met Glu Leu

95

100

105

agc agc ctg gcc tct gag gac tct gcg gtc tac tac tgt gca aga 360

Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg

110

115

120

ggg ggt tac tat agt tac gac gac tgg ggc caa ggc acc act ctc 405

Gly Gly Tyr Tyr Ser Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu

125

130

135

aca gtc tcc tca ggt ggt ggt tcg ggt ggt ggt tcg ggt 450

Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

140

145

150

ggt ggc gga tcg gat gtt gtg atg acc caa act cca ctc tcc ctg 495

Gly Gly Gly Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu

155

160

165

cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tct agt 540

Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser

170 175 180  
cag agc ctt cta cac agt aaa gga aac acc tat tta caa tgg tac 585  
Gln Ser Leu Leu His Ser Lys Gly Asn Thr Tyr Leu Gln Trp Tyr  
185 190 195  
cta cag aag cca ggc cag tct cca aag ctc ctg atc tac aaa gtt 630  
Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val  
200 205 210  
tcc aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga 675  
Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly  
215 220 225  
tca ggg aca gat ttc aca ctc aag atc agc aga gtg gag gct gag 720  
Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu  
230 235 240  
gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac 765  
Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr  
245 250 255  
acg tcc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac 810  
Thr Ser Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp  
260 265 270  
gat gac gat aaa taa tga 828  
Asp Asp Asp Lys

<210> 21  
<211> 31  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> PCR primer  
<400> 21

acgcgtcgac tcccaggtcc agctgcagca g 31

<210> 22

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 22

gaaggtgtat ccagaagc 18

<210> 23

<211> 819

<212> DNA

<213> Mus

<220>

<221> CDS

<222>(1)...(813)

<223> pCHOM1. MABL1-scFv

<400> 23

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca 45

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr

5 10 15

ggt gtc gac tcc cag gtc cag ctg cag cag tct gga cct gac ctg 90

Gly Val Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu

20 25 30

gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga 135

Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly

35 40 45

tac acc ttc gtt aac cat gtt atg cac tgg gtg aag cag aag cca 180  
 Tyr Thr Phe Val Asn His Val Met His Trp Val Lys Gln Lys Pro  
                   50                  55                  60  
 ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 225  
 Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp  
                   65                  70                  75  
 ggt act aag tac aat gag aag ttc aag ggc aag gcc aca ctg act 270  
 Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr  
                   80                  85                  90  
 tca gag aaa tcc tcc agc gca gcc tac atg gag ctc agc agc ctg 315  
 Ser Glu Lys Ser Ser Ala Ala Tyr Met Glu Leu Ser Ser Leu  
                   95                  100                105  
 gcc tct gag gac tct gcg gtc tac tac tgt gca aga ggg ggt tac 360  
 Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr  
                   110                115                120  
 tat agt tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcc 405  
 Tyr Ser Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser  
                   125                130                135  
 tca ggt ggt ggt tcg ggt ggt ggt tcg ggt ggt ggc gga 450  
 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly  
                   140                145                150  
 tcg gat gtt gtg atg acc caa act cca ctc tcc ctg cct gtc agt 495  
 Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser  
                   155                160                165  
 ctt gga gat caa gcc tcc atc tct tgc aga tct agt cag agc ctt 540  
 Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu  
                   170                175                180  
 cta cac agt aaa gga aac acc tat tta caa tgg tac cta cag aag 585  
 Leu His Ser Lys Gly Asn Thr Tyr Leu Gln Trp Tyr Leu Gln Lys

185	190	195
cca ggc cag tct cca aag ctc ctg atc tac aaa gtt tcc aac cga 630		
Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg		
200	205	210
TTT TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA 675		
Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr		
215	220	225
gat ttc aca ctc aag atc agc aga gtg gag gct gag gat ctg gga 720		
Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly		
230	235	240
gtt tat ttc tgc tctcaa agt aca cat gtt ccg tac acg tcc gga 765		
Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Ser Gly		
245	250	255
ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat 810		
Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp		
260	265	270
aaa taa tga 819		
Lys		

&lt;210&gt; 24

&lt;211&gt; 828

&lt;212&gt; DNA

&lt;213&gt; Mus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(822)

&lt;223&gt; pscM2. MABL2-scFv

&lt;400&gt; 24

atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc 45

整理番号=D O J - 5 4 6 7

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu  
5 10 15  
gct gcc caa cca gcc atg gcg cag gtc cag ctg cag cag tct gga 90  
Ala Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Gln Ser Gly  
20 25 30  
cct gaa ctg gta aag cct ggg gct tca gtg aag atg tcc tgc aag 135  
Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys  
35 40 45  
gct tct gga tac acc ttc gct aac cat gtt att cac tgg gtg aag 180  
Ala Ser Gly Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys  
50 55 60  
cag aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct 225  
Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro  
65 70 75  
tac aat gat ggt act aag tat aat gag aag ttc aag gac aag gcc 270  
Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala  
80 85 90  
act ctg act tca gac aaa tcc tcc acc aca gcc tac atg gac ctc 315  
Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu  
95 100 105  
agc agc ctg gcc tct gag gac tct gcg gtc tat tac tgt gca aga 360  
Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg  
110 115 120  
ggg ggt tac tat act tac gac gac tgg ggc caa ggc acc act ctc 405  
Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu  
125 130 135  
aca gtc tcc tca ggt ggt ggt tcg ggt ggt ggt tcg ggt 450  
Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly  
140 145 150

ggt ggc gga tcg gat gtt gtg atg acc caa agt cca ctc tcc ctg 495

Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu

155 160 165

cct gtc agt ctt gga gat caa gcc tcc atc tct tgc aga tca agt 540

Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser

170 175 180

cag agc ctt gtg cac agt aat gga aag acc tat tta cat tgg tac 585

Gln Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr

185 190 195

ctg cag aag cca ggc cag tct cca aaa ctc ctg atc tac aaa gtt 630

Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val

200 205 210

tcc aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga 675

Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly

215 220 225

tca gtg aca gat ttc aca ctc atg atc agc aga gtg gag gct gag 720

Ser Val Thr Asp Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu

230 235 240

gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac 765

Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr

245 250 255

acg ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac 810

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp

260 265 270

gat gac gat aaa taa tga 828

Asp Asp Asp Lys

<210> 25

<211> 819

整理番号=D O J - 5 4 6 7

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)...(813)

<223> pCHOM2. MABL2-scFv

<400> 25

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca 45

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr

5 10 15

ggt gtc gac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg 90

Gly Val Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu

20 25 30

gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga 135

Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly

35 40 45

tac acc ttc gct aac cat gtt att cac tgg gtg aag cag aag cca 180

Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro

50 55 60

ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 225

Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp

65 70 75

ggt act aag tat aat gag aag ttc aag gac aag gcc act ctg act 270

Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr

80 85 90

tca gac aaa tcc tcc acc aca gcc tac atg gac ctc agc agc ctg 315

Ser Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu

95 100 105

gcc tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt tac 360

Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr  
 110 115 120  
 tat act tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcc 405  
 Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser  
 125 130 135  
 tca ggt ggt ggt ggt tcg ggt ggt ggt tcg ggt ggt ggc gga 450  
 Ser Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly  
 140 145 150  
 tcg gat gtt gtg atg acc caa agt cca ctc tcc ctg cct gtc agt 495  
 Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser  
 155 160 165  
 ctt gga gat caa gcc tcc atc tct tgc aga tca agt cag agc ctt 540  
 Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu  
 170 175 180  
 gtg cac agt aat gga aag acc tat tta cat tgg tac ctg cag aag 585  
 Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys  
 185 190 195  
 cca ggc cag tct cca aaa ctc ctg atc tac aaa gtt tcc aac cga 630  
 Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg  
 200 205 210  
 ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tca gtg aca 675  
 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val Thr  
 215 220 225  
 gat ttc aca ctc atg atc agc aga gtg gag gct gag gat ctg gga 720  
 Asp Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu Asp Leu Gly  
 230 235 240  
 gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga 765  
 Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly  
 245 250 255

ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat 810

Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp

260

265

270

aaa taa tga 819

Lys

<210> 26

<211> 456

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)...(450)

<223> pCH0-shIAP. Soluble human IAP

<400> 26

atg tgg ccc ctg gta gcg gcg ctg ttg ctg ggc tcg gcg tgc tgc 45

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys

5

10

15

gga tca gct cag cta cta ttt aat aaa aca aaa tct gta gaa ttc 90

Gly Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe

20

25

30

acg ttt tgt aat gac act gtc gtc att cca tgc ttt gtt act aat 135

Thr Phe Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn

35

40

45

atg gag gca caa aac act act gaa gta tac gta aag tgg aaa ttt 180

Met Glu Ala Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe

50

55

60

aaa gga aga gat att tac acc ttt gat gga gct cta aac aag tcc 225

Lys Gly Arg Asp Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser

65	70	75
act gtc ccc act gac ttt agt agt gca aaa att gaa gtc tca caa 270		
Thr Val Pro Thr Asp Phe Ser Ser Ala Lys Ile Glu Val Ser Gln		
80	85	90
tta cta aaa gga gat gcc tct ttg aag atg gat aag agt gat gct 315		
Leu Leu Lys Gly Asp Ala Ser Leu Lys Met Asp Lys Ser Asp Ala		
95	100	105
gtc tca cac aca gga aac tac act tgt gaa gta aca gaa tta acc 360		
Val Ser His Thr Gly Asn Tyr Thr Cys Glu Val Thr Glu Leu Thr		
110	115	120
aga gaa ggt gaa acg atc atc gag cta aaa tat cgt gtt gtt tca 405		
Arg Glu Gly Glu Thr Ile Ile Glu Leu Lys Tyr Arg Val Val Ser		
125	130	135
tgg ttt tct cca aat gaa aat gac tac aag gac gac gat gac aag 450		
Trp Phe Ser Pro Asn Glu Asn Asp Tyr Lys Asp Asp Asp Asp Lys.		
140	145	150
tga tag 456		

&lt;210&gt; 27

&lt;211&gt; 46

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 27

ggaaattccat atgcaagtgc aacttcaaca gtctggacct gaactg 46

&lt;210&gt; 28

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 28

ggaattctca ttatttatt tccagcttgg t 31

&lt;210&gt; 29

&lt;211&gt; 741

&lt;212&gt; DNA

&lt;213&gt; Mus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(735)

&lt;223&gt; pscM2DEm02. MABL2-scFv

&lt;400&gt; 29

atg caa gtg caa ctt caa cag tct gga cct gaa ctg gta aag cct 45

Met Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro

5 10 15

ggg gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc 90

Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

20 25 30

gct aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc 135

Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly

35 40 45

ctt gag tgg att gga tat att tat cct tac aat gat ggt act aag 180

Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys

50 55 60

tat aat gag aag ttc aag gac aag gcc act ctg act tca gac aaa 225

Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys  
65 70 75  
tcc tcc acc aca gcc tac atg gac ctc agc agc ctg gcc tct gag 270  
Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu  
80 85 90  
gac tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act tac 315  
Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr  
95 100 105  
gac gac tgg ggc caa ggc acc act ctc aca gtc tcc tca ggt ggt 360  
Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly  
110 115 120  
ggt ggt tcg ggt ggt ggt tcg ggt ggt ggc gga tcg gat gtt 405  
Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Ser Asp Val  
125 130 135  
gtg atg acc caa agt cca ctc tcc ctg cct gtc agt ctt gga gat 450  
Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp  
140 145 150  
caa gcc tcc atc tct tgc aga tca agt cag agc ctt gtg cac agt 495  
Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser  
155 160 165  
aat gga aag acc tat tta cat tgg tac ctg cag aag cca ggc cag 540  
Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln  
170 175 180  
tct cca aaa ctc ctg atc tac aaa gtt tcc aac cga ttt tct ggg 585  
Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly  
185 190 195  
gtc cca gac agg ttc agt ggc agt gga tca gtg aca gat ttc aca 630  
Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val Thr Asp Phe Thr  
200 205 210

ctc atg atc agc aga gtg gag gct gag gat ctg gga gtt tat ttc 675

Leu Met Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe

215

220

225

tgc tct caa agt aca cat gtt ccg tac acg ttc gga ggg ggg acc 720

Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr

230

235

240

aag ctg gaa ata aaa taa tga

741

Lys Leu Glu Ile Lys

<210> 30

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 30

cagacagtgg ttcaaagt 18

<210> 31

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 31

cgcgtcgacc gatccgccac cacccgaacc accaccaccc gaaccaccac cactttat ttccag  
cttg gt 72

<210> 32

&lt;211&gt; 1605

&lt;212&gt; DNA

&lt;213&gt; Mus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1599)

&lt;223&gt; pCHOM2(Fv)2. MABL2-sc(Fv)2

&lt;400&gt; 32

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca 45

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr

5

10

15

ggt gtc gac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg 90

Gly Val Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu

20

25

30

gta aag cct ggg gct tca gtg aag atg tcc tgc aag gct tct gga 135

Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly

35

40

45

tac acc ttc gct aac cat gtt att cac tgg gtg aag cag aag cca 180

Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln Lys Pro

50

55

60

ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 225

Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp

65

70

75

ggt act aag tat aat gag aag ttc aag gac aag gcc act ctg act 270

Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr

80

85

90

tca gac aaa tcc tcc acc aca gcc tac atg gac ctc agc agc ctg 315

Ser Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu

95

100

105

gcc tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt tac 360  
 Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr  
 110 115 120  
 tat act tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcc 405  
 Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser  
 125 130 135  
 tca ggt ggt ggt tcg ggt ggt ggt tcg ggt ggt ggc gga 450  
 Ser Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Gly  
 140 145 150  
 tcg gat gtt gtg atg acc caa agt cca ctc tcc ctg cct gtc agt 495  
 Ser Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser  
 155 160 165  
 ctt gga gat caa gcc tcc atc tct tgc aga tca agt cag agc ctt 540  
 Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu  
 170 175 180  
 gtg cac agt aat gga aag acc tat tta cat tgg tac ctg cag aag 585  
 Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys  
 185 190 195  
 cca ggc cag tct cca aaa ctc ctg atc tac aaa gtt tcc aac cga 630  
 Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg  
 200 205 210  
 ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tca gtg aca 675  
 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val Thr  
 215 220 225  
 gat ttc aca ctc atg atc agc aga gtg gag gct gag gat ctg gga 720  
 Asp Phe Thr Leu Met Ile Ser Arg Val Glu Ala Glu Asp Leu Gly  
 230 235 240  
 gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga 765  
 Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly

245	250	255
ggg ggg acc aag ctg gaa ata aaa ggt ggt ggt ggt tcg ggt ggt 810		
Gly Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Ser Gly Gly		
260	265	270
ggt ggt tcg ggt ggt ggc gga tcg gtc gac tcc cag gtc cag ctg 855		
Gly Gly Ser Gly Gly Ser Val Asp Ser Gln Val Gln Leu		
275	280	285
cag cag tct gga cct gaa ctg gta aag cct ggg gct tca gtg aag 900		
Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys		
290	295	300
atg tcc tgc aag gct tct gga tac acc ttc gct aac cat gtt att 945		
Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asn His Val Ile		
305	310	315
cac tgg gtg aag cag aag cca ggg cag ggc ctt gag tgg att gga 990		
His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly		
320	325	330
tat att tat cct tac aat gat ggt act aag tat aat gag aag ttc 1035		
Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe		
335	340	345
aag gac aag gcc act ctg act tca gac aaa tcc tcc acc aca gcc 1080		
Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala		
350	355	360
tac atg gac ctc agc agc ctg gcc tct gag gac tct gcg gtc tat 1125		
Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr		
365	370	375
tac tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa 1170		
Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Asp Asp Trp Gly Gln		
380	385	390
ggc acc act ctc aca gtc tcc tca ggt ggt ggt ggt tcg ggt ggt 1215		

Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Ser Gly Gly

395

400

405

ggt ggt tcg ggt ggc gga tcg gat gtt gtg atg acc caa agt 1260

Gly Gly Ser Gly Gly Ser Asp Val Val Met Thr Gln Ser

410

415

420

cca ctc tcc ctg cct gtc agt ctt gga gat caa gcc tcc atc tct 1305

Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser

425

430

435

tgc aga tca agt cag agc ctt gtg cac agt aat gga aag acc tat 1350

Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Lys Thr Tyr

440

445

450

tta cat tgg tac ctg cag aag cca ggc cag tct cca aaa ctc ctg 1395

Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu

455

460

465

atc tac aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg ttc 1440

Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe

470

475

480

agt ggc agt gga tca gtg aca gat ttc aca ctc atg atc agc aga 1485

Ser Gly Ser Gly Ser Val Thr Asp Phe Thr Leu Met Ile Ser Arg

485

490

495

gtg gag gct gag gat ctg gga gtt tat ttc tgc tct caa agt aca 1530

Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr

500

505

510

cat gtt ccg tac acg ttc gga ggg ggg acc aag ctg gaa ata aaa 1575

His Val Pro Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys

515

520

525

gac tac aaa gac gat gac gat aaa taa tga

1605

Asp Tyr Lys Asp Asp Asp Asp Lys

530

<210> 33

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 33

tgaggaattc ccaccatggg atg 33

<210> 34

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 34

cacgacgtca ctcgagactg tgagagtgg gccttggccc 40

<210> 35

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 35

agtctcgagt gacgtcgtga tgacccaaag tccactctcc 40

<210> 36

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 36

gactggatcc tcattattta tcgtcatcgt c 31

<210> 37

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 37

cgcgtataac gactcaactat ag 22

<210> 38

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 38

gcaattggac ctgttttate tcgagcttgg tccccctcc gaacgt 46

<210> 39

<211> 45

<212> DNA

整理番号=D O J - 5 4 6 7

提出日 平成12年10月20日  
頁： 83/ 97

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 39

gctcgagata aaacagggtcc aattgcagca gtctggacct gaact 45

<210> 40

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 40

gactggatcc tcattattta tcgtcatacg tttttagtc tgaggagact gtgagagtgg 60

<210> 41

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 41

gactgaattc ccaccatgaa gttgcctgtt ag 32

<210> 42

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 42

cagtctcgag tggtggttcc gacgtcgtga tgacccaaag 40

<210> 43

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 43

cagtctcgag tggtggtggt tccgacgtcg tgatgaccca aag 43

<210> 44

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 44

cagtctcgag tggtggtggt gttccgacg tcgtgatgac ccaaag 46

<210> 45

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 45

cagtctcgag tggtggtggt ggtggttccg acgtcgtgat gacccaaag 49

<210> 46

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 46

cagtctcgag tggtggtggt ggtggttccg ccgacgtcgt gatgacccaa ag 52

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 47

ggccgcatgt tgtcacgaat 20

<210> 48

<211> 780

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)...(768)

<223> CF2HL-0/pCOS1. MABL2-scFv<HL-0>

<400> 48

atg gga tgg agc tgt atc atc ctc ttc ttg gta gca aca gct aca ggt gtc 51  
MET Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val

gac tcc cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag cct ggg 102  
Asp Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly

gct tca gtg aag atg tcc tgc aag gct tct gga tac acc ttc gct aac cat 153  
Ala Ser Val Lys MET Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asn His

gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt gag tgg att gga 204  
Val Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly

tat att tat cct tac aat gat ggt act aag tat aat gag aag ttc aag gac 255  
Tyr Ile Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp

aag gcc act ctg act tca gac aaa tcc tcc acc aca gcc tac atg gac ctc 306  
Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala Tyr MET Asp Leu

agc agc ctg gcc tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt 357  
Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly

tac tat act tac gac gac tgg ggc caa ggc acc act ctc aca gtc tcg agt 408  
Tyr Tyr Thr Tyr Asp Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser

gac gtc gtg atg acc caa agt cca ctc tcc ctg cct gtc agt ctt gga gat 459  
Asp Val Val MET Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp

caa gcc tcc atc tct tgc aga tca agt cag agc ctt gtg cac agt aat gga 510  
Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly

aag acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca aaa ctc 561  
Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu

ctg atc tac aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg ttc agt 612  
Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser

ggc agt gga tca gtg aca gat ttc aca ctc atg atc agc aga gtg gag gct 663  
Gly Ser Gly Ser Val Thr Asp Phe Thr Leu MET Ile Ser Arg Val Glu Ala

gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg 714  
Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr

ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat 765  
Phe Gly Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp

aaa taa tga gga tcc 780  
Lys

<210> 49

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 49

caagctcgag ataaaatccg gaggccaggt ccaattgcag cagtc 45

<210> 50

整理番号=D O J - 5 4 6 7

提出日 平成12年10月20日  
頁： 88/ 97

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 50

caagctcgag ataaaatccg gaggtggcca ggtccaattt cagcagtc 48

○  
<210> 51

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 51

caagctcgag ataaaatccg gaggtggtgg ccaggtccaa ttgcagcagt c 51

○  
<210> 52

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 52

caagctcgag ataaaatccg gaggtggtgg tggccaggc caattgcagc agtc 54

<210> 53

<211> 57

<212> DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 53

caagctcgag ataaaatccg gaggtggtgg tgggccag gtccattgc agcagtc 57

&lt;210&gt; 54

&lt;211&gt; 780

&lt;212&gt; DNA

&lt;213&gt; Mus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(768)

&lt;223&gt; CF2LH-0/pCOS1. MABL2-scFv&lt;LH-0&gt;

&lt;400&gt; 54

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct ggt tcc 51  
MET Lys Leu Pro Val Arg Leu Leu Val Leu MET Phe Trp Ile Pro Gly Seragc agt gat gtt gtg atg acc caa agt cca ctc tcc ctg cct gtc agt ctt 102  
Ser Ser Asp Val Val MET Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leugga gat caa gcc tcc atc tct tgc aga tca agt cag agc ctt gtg cac agt 153  
Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Seraat gga aag acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca 204  
Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Proaaa ctc ctg atc tac aaa gtt tcc aac cga ttt tct ggg gtc cca gac agg 255  
Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg

ttc agt ggc agt gga tca gtg aca gat ttc aca ctc atg atc agc aga gtg 306  
Phe Ser Gly Ser Gly Ser Val Thr Asp Phe Thr Leu MET Ile Ser Arg Val

gag gct gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg 357  
Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro

tac acg ttc gga ggg ggg acc aag ctc gag ata aaa cag gtc caa ttg cag 408  
Tyr Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Gln Val Gln Leu Gln

cag tct gga cct gaa ctg gta aag cct ggg gct tca gtg aag atg tcc tgc 459  
Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys MET Ser Cys

aag gct tct gga tac acc ttc gct aac cat gtt att cac tgg gtg aag cag 510  
Lys Ala Ser Gly Tyr Thr Phe Ala Asn His Val Ile His Trp Val Lys Gln

aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 561  
Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Asp

ggt act aag tat aat gag aag ttc aag gac aag gcc act ctg act tca gac 612  
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp

aaa tcc tcc acc aca gcc tac atg gac ctc agc agc ctg gcc tct gag gac 663  
Lys Ser Ser Thr Thr Ala Tyr MET Asp Leu Ser Ser Leu Ala Ser Glu Asp

tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg 714  
Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp

ggc caa ggc acc act ctc aca gtc tcc tca gac tac aaa gac gat gac gat 765

Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Asp Tyr Lys Asp Asp Asp Asp

aaa taa tga gga tcc

780

Lys

【図面の簡単な説明】

【図1】

ヒト IgG1抗体が、ヒトIAPを発現するL1210細胞(hIAP/L1210)に結合しないことを示すフローサイトメトリーの結果を示す図である。

【図2】

キメラMABL-1抗体が、ヒトIAPを発現するL1210細胞(hIAP/L1210)に特異的に結合することを示すフローサイトメトリーの結果を示す図である。

【図3】

キメラMABL-2抗体が、ヒトIAPを発現するL1210細胞(hIAP/L1210)に特異的に結合することを示すフローサイトメトリーの結果を示す図である。

【図4】

本発明にかかる一本鎖Fvの作成方法を模式的に示す図である。

【図5】

本発明の一本鎖FvをコードするDNAを、大腸菌にて発現させるために使用可能な発現プラスミドの一例の構造を示す。

【図6】

本発明の一本鎖FvをコードするDNAを、哺乳動物細胞にて発現させるために使用する発現プラスミドの一例の構造を示す。

【図7】

実施例5.4で得られたウエスタンプロットの結果を示す写真である。左側より、分子量マーカー(上から97.4、66、45、31、21.5、14.5kDaを示す)、pCHO1導入COS7細胞培養上清、pCHOM2導入細胞培

[BRIEF EXPLANATION OF DRAWINGS]

Figure 1 shows the result of flow cytometry, illustrating that human IgG antibody does not bind to L1210 cells expressing human IAP (hIAP/L1210).

5           Figure 2 shows the result of flow cytometry, illustrating that the chimera MABL-1 antibody specifically binds to L1210 cells expressing human IAP (hIAP/L1210).

10          Figure 3 shows the result of flow cytometry, illustrating that the chimera MABL-2 antibody specifically binds to L1210 cells expressing human IAP (hIAP/L1210).

Figure 4 schematically illustrates the process for producing the single-chain Fv according to the present invention..

15          Figure 5 illustrates a structure of an expression plasmid which can be used to express a DNA encoding the single-chain Fv of the invention in E. coli.

Figure 6 illustrates a structure of an expression plasmid which is used to express a DNA encoding the single-chain Fv of the invention in mammalian cells.

20          Figure 7 shows a photograph showing the result of western blotting in Example 5.4. From the left, a molecular weight marker (which indicates 97.4, 66, 45, 31, 21.5 and 14.5 kDa from the top), the culture supernatant of pCHO1-introduced COS7 cells and the culture supernatant of pCHOM2-introduced COS7 cells. It illustrates that the reconstructed single-chain Fv of the antibody MABL-2 (arrow) is contained in the culture supernatant of the pCHOM2-introduced cells.

Figure 8 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of pCHO1/COS7 cell as a control does not bind to pCOS1/L1210 cell as a control.

5 Figure 9 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of MABL2-scFv/COS7 cells does not bind to pCOS1/L1210 cells as a control.

10 Figure 10 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of pCOS1/COS7 cells as a control does not bind to hIAP/L1210 cells.

15 Figure 11 shows the result of flow cytometry, illustrating that an antibody in the culture supernatant of MABL2-scFv/COS7 cells specifically binds to hIAP/L1210 cells.

20 Figure 12 shows the result of the competitive ELISA in Example 5.6, wherein the binding activity of the single-chain Fv of the invention (MABL2-scFv) to the antigen is demonstrated in terms of the inhibition of binding of the mouse monoclonal antibody MABL-2 to the antigen as an index, in comparison with the culture supernatant of pCHO1/COS7 cells as a control.

25 Figure 13 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of pCHO1/COS7 cells as a

control does not induce the apoptosis of pCOS1/L1210 cells as a control.

Figure 14 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of MABL2-scFv/COS7 cells does not induce apoptosis of pCOS1/L1210 cells as a control.

Figure 15 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of pCHO1/COS7 cells as a control does not induce apoptosis of hIAP/L1210 cells.

Figure 16 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of MABL2-scFv/COS7 cells specifically induces apoptosis of hIAP/L1210 cells.

Figure 17 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of pCHO1/COS7 cells as a control does not induce apoptosis of CCRF-CEM cells (at 50% of the final concentration).

Figure 18 shows the results of the apoptosis-inducing effect in Example 5.7, illustrating that the antibody in the culture supernatant of MABL2-scFv/COS7 cells specifically induces apoptosis of CCRF-CEM cells (at 50% of the final concentration).

Figure 19 shows the chromatogram obtained in the purification of the single-chain Fv derived from the antibody MABL-2 produced by the CHO cells in Example 5.9,

illustrating that fraction A and fraction B were obtained as the major peaks when the fraction from Blue-sepharose column was purified with hydroxyapatite column.

Figure 20 shows the results of purification by gel filtration of fraction A and fraction B obtained in Example 5.9-(2), illustrating that the major peaks (AI and BI, respectively) were eluted from fraction A at approximately 36 kD of the apparent molecular weight and from fraction B at approximately 76 kD.

Figure 21 is the analysis on SDS-PAGE of the fractions obtained in the purification of the single chain Fv derived from the antibody MABL-2 produced by the CHO cells in Example 5.9, illustrating that a single band of approximately 35 kD of molecular weight was observed in both fractions.

Figure 22 shows the results of analysis of fractions AI and BI obtained by gel filtration in the purification of the single-chain Fv derived from the antibody MABL-2 produced by the CHO cells, wherein fraction AI comprises monomer and fraction BI comprises dimer.

Figure 23 illustrates a structure of an expression plasmid which can be used to express a DNA encoding the single-chain Fv of the invention in E. coli.

Figure 24 shows the results of purification on the gel filtration column of crude products of the single-chain Fv polypeptide derived from the antibody MABL-2 produced by E. coli obtained in Example 5.12, wherein each peak

indicates monomer or dimer, respectively, of the single-chain Fv produced by E. coli.

Figure 25 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that mouse IgG antibody as a control does not induce apoptosis of hIAP/L1210 cells (the final concentration of 3  $\mu$ g/ml).  
5

Figure 26 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that the dimer of MABL2-scFv produced by the CHO cells remarkably induces apoptosis of hIAP/L1210 cells (the final concentration of 3  
10  $\mu$ g/ml).  
10

Figure 27 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that the dimer of MABL2-scFv produced by E. coli remarkably induces apoptosis of hIAP/L1210 cells (the final concentration of 3  
15  $\mu$ g/ml).  
15

Figure 28 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that apoptosis induction to hIAP/L1210 cells by the MABL2-scFv monomer produced by the CHO cells is the same level as that of the control (the final concentration of 3  $\mu$ g/ml).  
20  
20

Figure 29 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that apoptosis induction to hIAP/L1210 cells of the MABL2-scFv monomer produced by E. coli is the same level as that of control  
25 (the final concentration of 3  $\mu$ g/ml).  
25

Figure 30 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that mouse IgG antibody used as a control does not induce apoptosis of hIAP/L1210 cells even when anti-FLAG antibody is added (the final concentration of 3 µg/ml).

Figure 31 shows the results of the apoptosis-inducing effect in Example 5.13, illustrating that MABL2-scFv monomer produced by the CHO cells remarkably induces apoptosis of hIAP/L1210 cells when anti-FLAG antibody is added (the final concentration of 3 µg/ml).

Figure 32 shows the results of quantitative measurement of human IgG in the serum of a human myeloma cell line KPMM2-transplanted mouse, indicating amounts of human IgG produced by the human myeloma cells in the mouse. It illustrates that the dimer of scFv/CHO remarkably inhibited growth of the KPMM2 cells.

Figure 33 shows the survival time of the mouse after the transplantation of tumor, illustrating that the scFv/CHO dimer-administered group elongated remarkably the survival time.

Figure 34 illustrates a structure of an expression plasmid which expresses a reconstructed polypeptide [sc(Fv)<sub>2</sub>] comprising two H chain V regions and two L chain V regions derived from the antibody MABL-2.

Figure 35 illustrates a structure of a plasmid which expresses a scFv (HL type) wherein the V regions are

linked in the manner of [H chain]-[L chain] without a peptide linker.

Figure 36 illustrates a structure of the HL-type polypeptide and amino acid sequences of peptide linkers.

5                  Figure 37 illustrates a structure of a plasmid which expresses a scFv (LH type) wherein the V regions are linked in the manner of [L chain]-[H chain] without a peptide linker.

10                Figure 38 illustrates a structure of the LH-type polypeptide and amino acid sequences of peptide linkers.

15                Figure 39 shows the results of the western blotting in Example 6.4, illustrating that the reconstructed polypeptide sc(FV)<sub>2</sub> comprising two H chain V regions and two L chain V regions, and the MABL2-scFv having peptide linkers with different length are expressed.

20                Figures 40 shows the results of flow cytometry using the culture supernatant of COS7 cells prepared in Example 6.3 (1), illustrating that the MABL2-scFv and sc(Fv)<sub>2</sub> having peptide linkers with different length have high affinities against human IAP.

25                Figure 41 shows the results of the apoptosis-inducing effect in Example 6.6, illustrating that the scFv <HL3, 4, 6, 7, LH3, 4, 6 and 7> and the sc(Fv)<sub>2</sub> remarkably induce cell death of hIAP/L1210 cells.

Figure 42 shows the results of the evaluation of antigen binding capacity in Example 6.10, illustrating that

the dimer of scFv <HL5> and sc(Fv)<sub>2</sub> have high affinities against human IAP.

5

Figure 43 shows the results of the in vitro apoptosis-inducing effect in Example 6.11, illustrating that the dimer of scFv <HL5> and the sc(Fv)<sub>2</sub> induce apoptosis of hIAP/L1210 cells and CCRF-CEM cells in concentration-dependent manner.

[Document] ABSTRACT



[Summary]

[Means to solve the problem]


This invention relates to reconstructed polypeptides which have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. The reconstructed polypeptides comprise two or more H chain V regions and two or more L chain V regions of a monoclonal antibody which induces apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.


[Selected Drawing] None

【書類名】 図面


【図1】  
Fig.【図2】  
Fig.


【図3】  
Fig.




[図4]  
Fig.



【図5】  
(Fig.)




【図6】  
Fig.

【図7】  
Fig.






[図8]  
Fig.[図9]  
Fig.



【図10】  
*Fig.*





【図11】  
*Fig.*




【図12】  
(Fig.)**Competitive ELISA**【図13】  
(Fig.)


[図14]  
Fig.[図15]  
Fig.

【図16】  
Fig.【図17】  
Fig.


【図18】  
(Fig.)



【図19】  
~~Fig.~~




【図20】  
Fig.




[図21]  
Fig.**SDS-PAGE analysis of MABL2-scFv**

&lt;CHO&gt;




&lt;E. coli&gt;




【図22】  
Fig.


TSK gel G3000SW  
20 mM Acetate buffer, 0.15 M NaCl, pH 6.0




【図23】  
Fig.




【図24】  
~~F.9~~




【図25】  
Fig.




【図26】  
Fig.






〔図27〕  
~~Fig.~~




【図28】  
Fig.



[図29]  
Fig.[図30]  
Fig.


【図31】  
Fig.【図32】  
Fig.

**Effect of MABL-2 (scFv) on serum hIgG  
in KPMM2 i.v. SCID mice**




【図33】

Fig.

***Effect of MABL-2 (scFv) on survival  
of KPMM2 i.v. SCID mice***

\*\* ; P&lt;0.01 by t-test

[図34]  
Fig.



【図35】  
Fig.

Fig. [図36]

H-L-type polypeptide and amino acid sequences of peptide linkers  
<HLタイプのリンカー塩基配列とアミノ酸配列>



Plasmid	Number of linker amino acid	linker	
		linker amino acid	linker
CF2HL-0/pCOS1	0	gtc tcg agt V S S	gac gtc gtg D V V
CF2HL-3/pCOS1	3	gtc tcg agt ggt ggt tcc V S S G G S	gac gtc gtg D V V
CF2HL-4/pCOS1	4	gtc tcg agt ggt ggt ggt tcc V S S G G G S	gac gtc gtg D V V
CF2HL-5/pCOS1	5	gtc tcg agt ggt ggt ggt ggt tcc V S S G G G G S	gac gtc gtg D V V
CF2HL-6/pCOS1	6	gtc tcg agt gt egt ggt ggt ggt tcc V S S G G G G G S	gac gtc gtg D V V
CF2HL-7/pCOS1	7	gtc tcg agt ggt ggt ggt ggt ggt tcc V S S G G G G G G S	gac gtc gtg D V V




【図37】  
Fig.


Fig. [図38]

## LH-type poly peptide and amino acid Sequences of peptide linkers. <LHタイプのリンカーリン基配列とアミノ酸配列>




Plasmid	Number of		linker
	linker	amino acid	
CF2LH-0/pCOS1	0	gag ata aaa E I K	cag gtc caa Q V Q
CF2LH-3/pCOS1	3	gag ata aaa tcc gga ggc E I K S G G	cag gtc caa Q V Q
CF2LH-4/pCOS1	4	gag ata aaa tcc gga ggt ggc E I K S G G G	cag gtc caa Q V Q
CF2LH-5/pCOS1	5	gag ata aaa tcc gga ggt ggt ggc E I K S G G G G	cag gtc caa Q V Q
CF2LH-6/pCOS1	6	gag ata aaa tcc gga ggt ggt ggt ggc E I K S G G G G G	cag gtc caa Q V Q
CF2LH-7/pCOS1	7	gag ata aaa tcc gga ggt ggt ggt ggt ggc E I K S G G G G G G Q V Q	cag gtc caa

【図39】  
Fig.

[図40]  
Fig.


【図41】


(Fig.)



【図42】

Fig.

**Reactivity of MABL-2 derivatives with pCOS1/L1210 (A) and hIAP/L1210 (B) cells**

[図43]  
Fig.**Apoptosis on hIAP/L1210 (A) and CCRF-CEM (B) cells  
by Annexin V-staining**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**